

09 | 960, 720

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 09 CA/CAPlus records now contain indexing from 1907 to the  
present  
NEWS 4 DEC 08 INPADOC: Legal Status data reloaded  
NEWS 5 SEP 29 DISSABS now available on STN  
NEWS 6 OCT 10 PCTFULL: Two new display fields added  
NEWS 7 OCT 21 BIOSIS file reloaded and enhanced  
NEWS 8 OCT 28 BIOSIS file segment of TOXCENTER reloaded and enhanced  
NEWS 9 NOV 24 MSDS-CCOHS file reloaded  
NEWS 10 DEC 08 CABA reloaded with left truncation  
NEWS 11 DEC 08 IMS file names changed  
NEWS 12 DEC 09 Experimental property data collected by CAS now available  
in REGISTRY  
NEWS 13 DEC 09 STN Entry Date available for display in REGISTRY and CA/CAPlus  
NEWS 14 DEC 17 DGENE: Two new display fields added  
NEWS 15 DEC 18 BIOTECHNO no longer updated  
NEWS 16 DEC 19 CROPU no longer updated; subscriber discount no longer  
available  
NEWS 17 DEC 22 Additional INPI reactions and pre-1907 documents added to CAS  
databases.  
NEWS 18 DEC 22 IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields  
NEWS 19 DEC 22 ABI-INFORM now available on STN  
NEWS 20 JAN 27 Source of Registration (SR) information in REGISTRY updated  
and searchable  
NEWS 21 JAN 27 A new search aid, the Company Name Thesaurus, available in  
CA/CAPlus  
  
NEWS EXPRESS DECEMBER 28 CURRENT WINDOWS VERSION IS V7.00, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

\*GENBANK - Genetic Sequence Data Bank

\* The files listed above are temporarily unavailable.

FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jan 30, 2004 (20040130/UP).

=> file medline, uspatful, dgene, embase, wpids, fsta, japio, biosis, cen, ceaba, biobusiness, hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.12	0.33

FILE 'MEDLINE' ENTERED AT 16:16:22 ON 04 FEB 2004

FILE 'USPATFULL' ENTERED AT 16:16:22 ON 04 FEB 2004

CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'FSTA' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 International Food Information Service

FILE 'JAPIO' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 Japanese Patent Office (JPO)- JAPIO

FILE 'BIOSIS' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CEN' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (c) 2004 DECHEMA eV

FILE 'BIOBUSINESS' ENTERED AT 16:16:22 ON 04 FEB 2004

COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s fibrosis () treatment

L1 993 FIBROSIS (W) TREATMENT

=> s fibrosis and cirrhosis

L2 45818 FIBROSIS AND CIRRHOSIS

=> s chronic pancreatitis

L3 1 CHRONIC PANCREATITIS

=> d l3 ti abs ibib tot

L3 ANSWER 1 OF 1 USPATFULL on STN

TI Treatment with small peptides to effect antifibrotic activity

AB Methods for treating treating fibrosis in a mammal are described. An antifibrotic effective amount of a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr is administered to the mammal. The fibrosis may be due to pathological changes resulting, e.g., from pulmonary fibrosis, atherosclerosis, cirrhosis, glomerulosclerosis, **chronic pancreatitis**, coronary artery disease (such as caused by infection by bacterium Chlamydia pneumoniae), trauma or surgical procedures. Examples of surgical procedures that cause fibrosis are post-operative fibrosis peri-neurally in the dura or nerve roots following spinal surgery, tenolysis of injured or repaired tendons with adhesions, neurolysis of damaged or repaired peripheral nerves with adhesions, post-operative adhesions from gynecologic and abdominal surgeries, reparative surgery of the vas deferens or fallopian tubes for reversal of male or female sterilization, and surgical repair of other tubular structures such as urethra, intestine or esophagus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:141513 USPATFULL

TITLE: Treatment with small peptides to effect antifibrotic activity

INVENTOR(S): Clagett, James, Snohomish, WA, UNITED STATES

PATENT ASSIGNEE(S): Histatek, Inc. (U.S. corporation)

App

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072499	A1	20020613
APPLICATION INFO.:	US 2001-960720	A1	20010921 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US7411, filed on 20 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-125514P	19990322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Edwards & Angell, LLP, P.O. Box 9169, Boston, MA, 02209	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN, CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITIS

=> s l2 and l1  
L4 95 L2 AND L1

=> s f-Met-Leu  
L5 2524 F-MET-LEU

=> s N-formyl peptides  
L6 346 N-FORMYL PEPTIDES

=> s l6 and l1  
L7 0 L6 AND L1

=> l5 and l1  
L5 IS NOT A RECOGNIZED COMMAND  
The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s l5 and l1  
L8 1 L5 AND L1

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
TI Treatment with small peptides to effect antifibrotic activity  
AB Methods for treating fibrosis in a mammal are described. An  
antifibrotic-effective amount of a peptide f-Met-  
Leu-X (X = Tyr, Tyr-Phe, Phe-Phe, Phe-Tyr) is administered to the  
mammal. The fibrosis may be due to pathol. changes resulting, e.g., from  
pulmonary fibrosis, atherosclerosis, cirrhosis, glomerulosclerosis,  
chronic pancreatitis, coronary artery disease (such as caused by infection  
by bacterium Chlamydia pneumoniae, trauma or surgical procedures).  
Examples of surgical procedures that cause fibrosis are post-operative  
fibrosis peri-neurally in the dura or nerve roots following spinal  
surgery, tenolysis of injured or repaired tendons with adhesions,  
neurolysis of damaged or repaired peripheral nerves with adhesions,  
post-operative adhesions from gynecol. and abdominal surgeries, reparative  
surgery of the vas deferens or fallopian tubes for reversal of male or  
female sterilization, and surgical repair of other tubular structures such  
as urethra, intestine or esophagus.

ACCESSION NUMBER: 2000:688103 HCAPLUS  
DOCUMENT NUMBER: 133:247310  
TITLE: Treatment with small peptides to effect antifibrotic  
activity  
INVENTOR(S): Clagett, James  
PATENT ASSIGNEE(S): Histatek, LLC, USA  
SOURCE: PCT Int. Appl., 44 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000056349	A1	20000928	WO 2000-US7411	20000320
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,			

SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1162990 A1 20011219 EP 2000-916561 20000320  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 BR 2000009226 A 20011226 BR 2000-9226 20000320  
 JP 2002539270 T2 20021119 JP 2000-606253 20000320  
 NO 2001004594 A 20011121 NO 2001-4594 20010921  
 US 2002072499 A1 20020613 US 2001-960720 20010921  
 PRIORITY APPLN. INFO.: US 1999-125514P P 19990322  
 WO 2000-US7411 W 20000320  
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN,  
 CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
 L2 45818 S FIBROSIS AND CIRRHOSIS  
 L3 1 S CHRONIC PANCREATITUS  
 L4 95 S L2 AND L1  
 L5 2524 S F-MET-LEU  
 L6 346 S N-FORMYL PEPTIDES  
 L7 0 S L6 AND L1  
 L8 1 S L5 AND L1

=> d l4 ti abs ibib 1-20

L4 ANSWER 1 OF 95 MEDLINE on STN  
 TI Clinical observation on the anti-liver **fibrosis**  
**treatment** by diammonion glycyrrhizinate injection combined with  
 saliva.  
 ACCESSION NUMBER: 2003081815 MEDLINE  
 DOCUMENT NUMBER: 22481124 PubMed ID: 12592693  
 TITLE: Clinical observation on the anti-liver **fibrosis**  
**treatment** by diammonion glycyrrhizinate injection  
 combined with saliva.  
 AUTHOR: Zhang Yi-fa; Wang Lin-lun; Yin Wei-hua  
 SOURCE: CHUNG-KUO CHUNG HSI I CHIEH HO TSA CHIH, (2002 Jul) 22 (7)  
 538-9.  
 Journal code: 9211576. ISSN: 1003-5370.  
 PUB. COUNTRY: China  
 DOCUMENT TYPE: (CLINICAL TRIAL)  
 Journal; Article; (JOURNAL ARTICLE)  
 (RANDOMIZED CONTROLLED TRIAL)  
 LANGUAGE: Chinese  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200306  
 ENTRY DATE: Entered STN: 20030221  
 Last Updated on STN: 20030621  
 Entered Medline: 20030620

*bad date*

L4 ANSWER 2 OF 95 MEDLINE on STN  
 TI Developing strategies for liver **fibrosis treatment**.  
 AB Liver **fibrosis** represents a major worldwide healthcare burden.

Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of **fibrosis**. There is therefore a great need for novel therapies for liver **fibrosis**. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver **fibrosis**. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver **fibrosis**.

ACCESSION NUMBER: 2002678189 MEDLINE  
DOCUMENT NUMBER: 22326184 PubMed ID: 12437504  
TITLE: Developing strategies for liver **fibrosis** treatment.  
AUTHOR: Murphy Frank; Arthur Michael; Iredale John  
CORPORATE SOURCE: Liver Research Group, Division of Infection, Inflammation & Repair, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.. frml105@hotmail.com  
SOURCE: EXPERT OPINION ON INVESTIGATIONAL DRUGS, (2002 Nov) 11 (11) 1575-85. Ref: 109  
Journal code: 9434197. ISSN: 1354-3784.  
PUB. COUNTRY: England: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200303  
ENTRY DATE: Entered STN: 20021120  
Last Updated on STN: 20030326  
Entered Medline: 20030325

L4 ANSWER 3 OF 95 MEDLINE on STN

TI [Extracellular matrix, hepatic **fibrosis** and anti-**fibrosis** treatment].

Matrice extra-cellulaire, fibrose hepatique et traitements antifibrotiques.

AB Over recent years, the study of the extracellular matrix (ECM) in the liver has considerably progressed. The application of new biochemical and genetic techniques led to the discovery of 13 different collagen proteins and a growing number of collagen-associated proteins such as fibronectin, laminin and proteoglycans. Many of these proteins have been cloned and sequenced. Progress also includes a better knowledge of the biological roles of ECM components as well as its dynamic remodeling in various pathophysiological conditions. Even if the clinical goal of prophylaxis and therapy of **fibrosis** remains distant, progress can be anticipated in the near future as basic processes are being elucidated.

ACCESSION NUMBER: 91096568 MEDLINE  
DOCUMENT NUMBER: 91096568 PubMed ID: 2267901  
TITLE: [Extracellular matrix, hepatic **fibrosis** and anti-**fibrosis** treatment].  
Matrice extra-cellulaire, fibrose hepatique et traitements antifibrotiques.  
AUTHOR: Geubel A P  
CORPORATE SOURCE: Service de gastro-enterologie, Cliniques St Luc-Universite Catholique de Louvain.  
SOURCE: ACTA GASTROENTEROLOGICA BELGICA, (1990 Mar-Apr) 53 (2) 216-24. Ref: 25  
Journal code: 0414075. ISSN: 0001-5644.  
PUB. COUNTRY: Belgium  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
General Review; (REVIEW)  
(REVIEW, TUTORIAL)

LANGUAGE: French  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199102  
ENTRY DATE: Entered STN: 19910322  
Last Updated on STN: 19910322  
Entered Medline: 19910214

L4 ANSWER 4 OF 95 USPATFULL on STN

TI Anticancer products for treating cystic **fibrosis**

AB The invention concerns a novel approach for treating cystic **fibrosis** using, in particular, anti-cancer chemotherapy. For the treatment of cystic **fibrosis** it proposes the use of at least one product which when administered to a patient brings about the expression or overexpression of an ABC carrier compound, in particular glutathione carrier. Preferably, the products used are anti-cancer products whose administration brings about the expression of MRP and/or MDR protein. The invention is also applicable to the treatment of rheumatoid polyarthrititis or asthma.

ACCESSION NUMBER: 2004:13402 USPATFULL  
TITLE: Anticancer products for treating cystic **fibrosis**

INVENTOR(S): Stoven, Veronique, Paris, FRANCE  
Lenoir, Gerard, Paris, FRANCE  
Lallemant, Jean-Yves, Palaiseau, FRANCE  
Annereau, Jean-Philippe, Paris, FRANCE  
Barthe, Joel, Paris, FRANCE  
Blanquet, Sylvain, Paris, FRANCE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004009924	A1	20040115
APPLICATION INFO.:	US 2003-379713	A1	20030306 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1999-424785, filed on 29 Nov 1999, GRANTED, Pat. No. US 6635627 A 371 of International Ser. No. WO 1998-FR1074, filed on 28 May 1998, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1997-6667	19970530
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Finnegan, Henderson, Farabow,, Garrett & Dunner, L.L.P., 1300 I Street, N.W., Washington, DC, 20005-3315	
NUMBER OF CLAIMS:	7	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1189	

L4 ANSWER 5 OF 95 USPATFULL on STN

TI Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products

AB Methods of determining rate of biosynthesis or breakdown of biological molecules from metabolic derivatives and catabolic products are disclosed herein. In particular, methods of measuring the rates of biosynthesis and breakdown of biological molecules inaccessible or not easily accessible to direct sampling by sampling metabolic derivatives and catabolic products in accessible biological samples are disclosed herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:324286 USPATFULL  
TITLE: Measurement of biosynthesis and breakdown rates of biological molecules that are inaccessible or not easily accessible to direct sampling, non-invasively, by label incorporation into metabolic derivatives and catabolic products  
INVENTOR(S): Hellerstein, Marc K., Kensington, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003228259	A1	20031211
APPLICATION INFO.:	US 2003-366125	A1	20030212 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-356008P	20020212 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 425 MARKET STREET, SAN FRANCISCO, CA, 94105-2482	
NUMBER OF CLAIMS:	59	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	3036	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 6 OF 95 USPATFULL on STN  
TI Human tumor necrosis factor delta and epsilon  
AB The invention relates to human TNF delta and TNF epsilon polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:238706 USPATFULL  
TITLE: Human tumor necrosis factor delta and epsilon  
INVENTOR(S): Yu, Guo-Liang, Berkeley, CA, UNITED STATES  
Ni, Jian, Germantown, MD, UNITED STATES  
Gentz, Reiner, Belo Horizonte-Mg, BRAZIL

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166864	A1	20030904
APPLICATION INFO.:	US 2002-268951	A1	20021011 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-879919, filed on 14 Jun 2001, PENDING Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170 Continuation-in-part of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170 Continuation-in-part of Ser. No. US 2002-82260, filed on 26 Feb 2002, GRANTED, Pat. No. US 6506882 Division of Ser. No. US 1997-815783, filed on 12 Mar 1997, GRANTED, Pat. No. US 6509170		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-328401P	20011012 (60)
	US 2000-211537P	20000615 (60)
	US 2000-241952P	20001023 (60)
	US 2000-254875P	20001213 (60)
	US 2001-277978P	20010323 (60)



US 2001-276248P 20010316 (60)  
US 2001-293499P 20010525 (60)  
US 1996-16812P 19960314 (60)  
US 1996-16812P 19960314 (60)  
US 1996-16812P 19960314 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 50  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 11 Drawing Page(s)  
LINE COUNT: 14873  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 7 OF 95 USPATFULL on STN

TI Recombinant adenoviral vectors and their utility in the treatment of  
various types of **fibrosis**: hepatic, renal, pulmonary, as well  
as hypertrophic scars

AB SUMMARY OF THE INVENTION

The use of gene therapy for the treatment of different kinds of  
**fibrosis** in human beings is disclosed. The purpose is the use of  
"therapeutic2 genes specifically directed to target organs to revert  
and/or prevent the development of the **fibrosis** process.

The potential application of gene therapy to patients with  
**fibrosis** and/or **cirrhosis** will depend to a large  
extent on the successful delivery of genes which encode for therapeutic  
proteins to livers with severe **fibrosis** and that these genes  
which encode for proteins human MMP-8 active and latent, MMP-1, MMP-2,  
MMP-9 and MMP-13; human uPA wild type and/or modified (or its truncated  
version), the truncated receptor for TGF- $\beta$  type II and Smad-7 can  
be directed by adenovirus and/or other recombinant vectors that cannot  
transduce (infect) others organs. The recombinant adenoviruses (AdR) are  
vectors highly efficient for the transduction of therapeutic genes to  
diverse target cells. We have proved that they can carry genes to  
cirrhotic livers.

The delivery of therapeutic genes through such adenoviral vectors and  
other recombinant vectors could also be performed using cationic and  
anionic liposomes (DOTMA).

Therefore, we propose the use of this patent to be applied in the same  
manner to:

Renal **fibrosis**

Pulmonary **fibrosis**

Hypertrophic and keloid scars (skin **fibrosis**), and

Other kinds of **fibrosis**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:3043 USPATFULL

TITLE: Recombinant adenoviral vectors and their utility in the  
treatment of various types of **fibrosis**:  
hepatic, renal, pulmonary, as well as hypertrophic  
scars

INVENTOR(S): Armendariz Borunda, Juan, Prado Coapa, MEXICO  
Aguilar Cordova, Estuardo, Col. Prado Coapa, MEXICO

NUMBER KIND DATE

PATENT INFORMATION: US 2003003077 A1 20030102  
APPLICATION INFO.: US 2002-98359 A1 20020318 (10)  
RELATED APPLN. INFO.: Continuation of Ser. No. WO 2000-MX35, filed on 14 Sep  
2000, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	MX 1999-998515	19990917
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PENNIE & EDMONDS LLP, 1667 K STREET NW, SUITE 1000, WASHINGTON, DC, 20006	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1285	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 8 OF 95 USPATFULL on STN  
TI Cyanomethyl substituted thiazoliums and imidazoliums and treatments of  
disorders associated with protein aging  
AB Provided, among other things, is a compound of the formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
ACCESSION NUMBER: 2002:192111 USPATFULL  
TITLE: Cyanomethyl substituted thiazoliums and imidazoliums  
and treatments of disorders associated with protein  
aging  
INVENTOR(S): Wagle, Dilip R., New York, NY, UNITED STATES  
Fang, Sheng Ding, Mount Kisco, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002103182	A1	20020801
	US 6610716	B2	20030826
APPLICATION INFO.:	US 2001-905035	A1	20010713 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-218273P	20000713 (60)
	US 2001-296435P	20010606 (60)
	US 2001-259242P	20010102 (60)
	US 2000-259431P	20001229 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DECHERT, P.O. Box 5218, Princeton, NJ, 08543	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1895	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L4 ANSWER 9 OF 95 USPATFULL on STN  
TI Method for diagnosing and treating chronic pelvic pain syndrome  
AB The present invention provides a superior method of diagnosing Chronic  
Pelvic Pain Syndrome in men comprising measuring levels of cytokines in  
semen or components or fractions of semen. The invention also provides a  
method of treating a condition associated with elevated levels of a  
cytokine, such as TNF- $\alpha$ , in semen or a component or fraction  
thereof, comprising administering a therapeutically effective amount of  
an ant-cytokine compound or composition, such as an anti-TNF- $\alpha$   
compound or composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:14213 USPATFULL  
TITLE: Method for diagnosing and treating chronic pelvic pain syndrome  
INVENTOR(S): Alexander, Richard B., Ellicott City, MD, United States  
Ponniah, Sathibalan, Ellicott City, MD, United States  
PATENT ASSIGNEE(S): University of Maryland, Baltimore, Baltimore, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6180355	B1	20010130
APPLICATION INFO.:	US 1999-306927		19990507 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-84668P	19980507 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Schwartzman, Robert A.	
ASSISTANT EXAMINER:	Larson, Thomas G.	
LEGAL REPRESENTATIVE:	Hultquist, Steven J., Barrett, William A.	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	3501	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 10 OF 95 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

TI Developing strategies for liver **fibrosis** treatment.

AB Liver **fibrosis** represents a major worldwide healthcare burden. Current therapy is limited to removing the causal agent. This approach is successful in some diseases; particularly haemochromatosis and chronic viral hepatitis. However, for many patients treatment is not possible, while other patients present to medical attention at an advanced stage of **fibrosis**. There is therefore a great need for novel therapies for liver **fibrosis**. The hepatic stellate cell has been recognised to be responsible for most of the excess extracellular matrix observed in chronic liver **fibrosis**. The detailed understanding of hepatic stellate cell biology has allowed the rational design of novel antifibrotic therapies. This review describes for the general reader the novel emerging therapies for liver **fibrosis**.

ACCESSION NUMBER: 2002412952 EMBASE  
TITLE: Developing strategies for liver **fibrosis** treatment.  
AUTHOR: Murphy F.; Arthur M.; Iredale J.  
CORPORATE SOURCE: Dr. F. Murphy, Liver Research Group, Division of Infection Inflamm./Repair, University of Southampton, Southampton SO16 6YD, United Kingdom. frm105@hotmail.com  
SOURCE: Expert Opinion on Investigational Drugs, (1 Nov 2002) 11/11 (1575-1585).  
Refs: 109  
ISSN: 1354-3784 CODEN: EOIDER  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 030 Pharmacology  
037 Drug Literature Index  
038 Adverse Reactions Titles  
048 Gastroenterology  
LANGUAGE: English  
SUMMARY LANGUAGE: English

L4 ANSWER 11 OF 95 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI ANGIOTENSIN II TYPE 1A RECEPTOR DEFICIENT MICE SHOW SLOW PROGRESSION OF

LIVER FIBROSIS INDUCED BY CARBON TETRACHLORIDE: A DIRECT EVIDENCE FOR FIBROGENETIC ROLE OF RENIN-ANGIOTENSIN SYSTEM. .

AB Background and Aim:.. The renin-angiotensin system (RAS) has been shown to contribute to fibrogenesis in a variety of organs, including the liver. In some animal models, blockers of the action of angiotensin (Ang), such as angiotensin-converting enzyme (ACE) inhibitors or Ang II receptor antagonists, have been shown to induce regression or prevent the development of hepatic fibrosis. The aim of the present study was to determine whether the Ang II type 1A receptor (AT1A) is implicated in the development of liver fibrosis through Ang II signaling. Methods: Male AT1A-deficient mice and wild-type (WT) mice (7w) were administered with carbon tetrachloride (CCl4) (1 ml/kg) as a single intraperitoneal injection to assess the necrotic and inflammatory changes caused by acute exposure to CCl4. Liver fibrosis was induced by the subcutaneous injection of CCl4 (1 ml/kg) twice weekly for 4 weeks. The extent of necrosis/inflammation or fibrosis was evaluated in AT1A-deficient mice and wild-type (WT) mice with analyses of fibrotic parameters; (1) Liver histology, (2) Hepatic hydroxyproline content, (3) Immunohistochemical expression of hepatic  $\alpha$ -smooth muscle actin ( $\alpha$ -SMA), (4) TGF- $\beta$ 1 mRNA expression by RT-PCR. Results: After single dose of CCl4, there were no significant differences between WT mice and AT1A-deficient mice with regard to serum transaminase and TNF- $\alpha$  levels. Histologically, the extent of necrosis and inflammatory infiltration was similar in the two groups. After chronic administration of CCl4, histological examination revealed that AT1A-deficient mice showed less infiltration of monocytes and slower progression of liver fibrosis when compared with WT mice. These findings were accompanied by an increased hepatic content of hydroxyproline. WT mice treated with chronic CCl4 showed a 6.1-fold increment of the hydroxyproline content, whereas AT1A-deficient mice showed a more modest 2.6-fold increment. Immunohistochemical expression of  $\alpha$ -SMA was negligible in AT1A-deficient mice, while it was strongly detected in WT mice. The level of TGF- $\beta$ 1 mRNA was markedly higher in WT mice when compared with AT1A-deficient mice. Conclusions: These results suggested that signaling via AT1A plays a pivotal role in hepatic fibrogenesis, while AT1A blockade reduces the progression of liver fibrosis through the suppression of chronic inflammation. Thus, AT1A is a potentiated-molecular target for liver fibrosis treatment..

ACCESSION NUMBER: 2004:25813 BIOSIS

DOCUMENT NUMBER: PREV200400024212

TITLE: ANGIOTENSIN II TYPE 1A RECEPTOR DEFICIENT MICE SHOW SLOW PROGRESSION OF LIVER FIBROSIS INDUCED BY CARBON TETRACHLORIDE: A DIRECT EVIDENCE FOR FIBROGENETIC ROLE OF RENIN-ANGIOTENSIN SYSTEM. .

AUTHOR(S): Kanno, Keishi [Reprint Author]; Tazuma, Susumu [Reprint Author]; Nishioka, Tomoji [Reprint Author]; Hyogo, Hideyuki [Reprint Author]; Sunami, Yusushi [Reprint Author]; Nakai, Kuniharu [Reprint Author]; Tsuboi, Kazuhiko [Reprint Author]; Asamoto, Yasumasa [Reprint Author]; Numata, Yoshihiro [Reprint Author]; Yamaguchi, Atsushi [Reprint Author]; Kobuke, Toshiya [Reprint Author]; Komichi, Daisuke [Reprint Author]; Nonaka, Michihiro [Reprint Author]; Chayama, Kazuaki [Reprint Author]

CORPORATE SOURCE: Hiroshima, Japan

SOURCE: Digestive Disease Week Abstracts and Itinerary Planner, (2003) Vol. 2003, pp. Abstract No. 516. e-file. Meeting Info.: Digestive Disease 2003. FL, Orlando, USA. May 17-22, 2003. American Association for the Study of Liver Diseases; American Gastroenterological Association; American Society for Gastrointestinal Endoscopy; Society for Surgery of the Alimentary Tract.

DOCUMENT TYPE: Conference; (Meeting)  
Conference; (Meeting Poster)  
Conference; Abstract; (Meeting Abstract)

US 1998-92921P 19980715 (60)  
US 1998-94657P 19980730 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE,  
ROCKVILLE, MD, 20850  
NUMBER OF CLAIMS: 23  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 10 Drawing Page(s)  
LINE COUNT: 32746  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN,  
CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITUS  
L4 95 S L2 AND L1  
L5 2524 S F-MET-LEU  
L6 346 S N-FORMYL PEPTIDES  
L7 0 S L6 AND L1  
L8 1 S L5 AND L1  
L9 19 S L5 AND L6  
L10 365786 S FIBROSIS  
L11 0 S L10 AND VAS DEFERENS REPAIR  
L12 1 S L10 AND FALLOPIAN TUBE REPAIR

=> l10 and therapy

L10 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l10 and therapy

L13 109111 L10 AND THERAPY

=> s l13 and l6

L14 1 L13 AND L6

=> d l14 ti abs ibib ot

'OT' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS ----- AB

ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
EXF, ARTU

ALLG ----- ALL plus PAGE.DRAW

BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,  
PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT

BIB.EX ----- BIB for original and latest publication

BIBG ----- BIB plus PAGE.DRAW

BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must  
 entered on the same line as DISPLAY, e.g., D BROWSE.

CAS ----- OS, CC, SX, ST, IT

CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS

DALL ----- ALL, delimited for post-processing

FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,  
 PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,  
 NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,  
 CLMN, DRWN, AB

FP.EX ----- FP for original and latest publication

FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
 RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,  
 NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,  
 PARN, SUMM, DRWD, DETD, CLM

FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
 RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN

FHITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram

FPG ----- FP plus PAGE.DRAW

GI ----- PN and page image numbers

HIT ----- All fields containing hit terms

HITRN ----- HIT RN and its text modification

HITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram

IABS ----- ABS, indented with text labels

IALL ----- ALL, indented with text labels

IALLG ----- IALL plus PAGE.DRAW

IBIB ----- BIB, indented with text labels

IBIB.EX ----- IBIB for original and latest publication

IBIBG ----- IBIB plus PAGE.DRAW

IMAX ----- MAX, indented with text labels

IMAX.EX ----- IMAX for original and latest publication

IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
 EXF, ARTU, OS, CC, SX, ST, IT

ISTD ----- STD, indented with text labels

KWIC ----- All hit terms plus 20 words on either side

MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
 INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
 EXF, ARTU OS, CC, SX, ST, IT

MAX.EX ----- MAX for original and latest publication

OCC ----- List of display fields containing hit terms

SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
 DT, FS, LN.CNT

SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display  
 without answer number. SCAN must be entered on the  
 same line as DISPLAY, e.g., D SCAN)

STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
 DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,  
 IC, ICM, ICS, EXF (STD is the default)

STD.EX ----- STD for original and latest publication

TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,  
 ICM, ICS

ENTER DISPLAY FORMAT (STD):d his  
 'D' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'  
 'HIS' IS NOT A VALID FORMAT FOR FILE 'USPATFULL'

The following are valid formats:

The default display format is STD.

ABS ----- AB

ALL ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
 INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
 EXF, ARTU  
 ALLG ----- ALL plus PAGE.DRAW  
 BIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD, RLI,  
 PRAI, DT, FS, EXNAM, LREP, CLMN, ECL, DRWN, LN.CNT  
 BIB.EX ----- BIB for original and latest publication  
 BIBG ----- BIB plus PAGE.DRAW  
 BROWSE ----- See "HELP BROWSE" or "HELP DISPLAY BROWSE". BROWSE must  
 entered on the same line as DISPLAY, e.g., D BROWSE.  
 CAS ----- OS, CC, SX, ST, IT  
 CBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PRAI, DT, FS  
 DALL ----- ALL, delimited for post-processing  
 FP ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI, RLI,  
 PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL,  
 NCLM, NCLS, EXF, REP, REN, ARTU, EXNAM, LREP,  
 CLMN, DRWN, AB  
 FP.EX ----- FP for original and latest publication  
 FPALL ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
 RLI, PRAI, IC, ICM, ICS, INCL, INCLM, INCLS, NCL, NCLM,  
 NCLS, EXF, REP, REN, ARTU, EXNAM, LREP, CLMN, DRWN, AB,  
 PARN, SUMM, DRWD, DETD, CLM  
 FPBIB ----- PI, TI, IN, INA, PA, PAA, PAT, PTERM, DCD, AI,  
 RLI, PRAI, REP, REN, EXNAM, LREP, CLM, CLMN, DRWN  
 FHITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 FPG ----- FP plus PAGE.DRAW  
 GI ----- PN and page image numbers  
 HIT ----- All fields containing hit terms  
 HITRN ----- HIT RN and its text modification  
 HITSTR ----- HIT RN, its text modification, its CA index name, and  
 its structure diagram  
 IABS ----- ABS, indented with text labels  
 IALL ----- ALL, indented with text labels  
 IALLG ----- IALL plus PAGE.DRAW  
 IBIB ----- BIB, indented with text labels  
 IBIB.EX ----- IBIB for original and latest publication  
 IBIBG ----- IBIB plus PAGE.DRAW  
 IMAX ----- MAX, indented with text labels  
 IMAX.EX ----- IMAX for original and latest publication  
 IND ----- INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
 EXF, ARTU, OS, CC, SX, ST, IT  
 ISTD ----- STD, indented with text labels  
 KWIC ----- All hit terms plus 20 words on either side  
 MAX ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, PTERM, DCD,  
 RLI, PRAI, DT, FS, REP, REN, EXNAM, LREP, CLMN, ECL,  
 DRWN, AB, GOVI, PARN, SUMM, DRWD, DETD, CLM, INCL,  
 INCLM, INCLS, NCL, NCLM, NCLS, IC, ICM, ICS,  
 EXF, ARTU OS, CC, SX, ST, IT  
 MAX.EX ----- MAX for original and latest publication  
 OCC ----- List of display fields containing hit terms  
 SBIB ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
 DT, FS, LN.CNT  
 SCAN ----- AN, TI, NCL, NCLM, NCLS, IC, ICM, ICS (random display  
 without answer number. SCAN must be entered on the  
 same line as DISPLAY, e.g., D SCAN)  
 STD ----- AN, TI, IN, INA, PA, PAA, PAT, PI, AI, RLI, PRAI,  
 DT, FS, LN.CNT, INCL, INCLM, INCLS, NCL, NCLM, NCLS,  
 IC, ICM, ICS, EXF (STD is the default)  
 STD.EX ----- STD for original and latest publication  
 TRIAL ----- AN, TI, INCL, INCLM, INCLS, NCL, NCLM, NCLS, IC,  
 ICM, ICS

ENTER DISPLAY FORMAT (STD):end

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN, CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITUS  
L4 95 S L2 AND L1  
L5 2524 S F-MET-LEU  
L6 346 S N-FORMYL PEPTIDES  
L7 0 S L6 AND L1  
L8 1 S L5 AND L1  
L9 19 S L5 AND L6  
L10 365786 S FIBROSIS  
L11 0 S L10 AND VAS DEFERENS REPAIR  
L12 1 S L10 AND FALLOPIAN TUBE REPAIR  
L13 109111 S L10 AND THERAPY  
L14 1 S L13 AND L6

=> d l14 ti abs ibib tot

L14 ANSWER 1 OF 1. USPATFULL on STN

TI METHODS AND REAGENTS FOR REGULATION OF CELLULAR RESPONSES IN BIOLOGICAL SYSTEMS

AB Abstract of Disclosure

This invention provides multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can most generally function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and generally for macromolecular assembly of biological macromolecules. The multivalent ligands of this invention are generally applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors (cell surface receptors, transmembrane receptors and cytoplasmic receptors), and various macromolecules (nucleic acids, carbohydrates, saccharides, proteins, peptides, etc.). In these scaffolds, the number, spacing, relative positioning and relative orientation of recognition elements can be controlled. Multivalent ligands of this invention can carry or display at least one signal recognition element (SRE), and preferably a plurality of signal recognition elements, and modulate biological responses in biological systems. The invention also relates to methods for aggregating biological particles and macromolecules and for modulating biological response employing the multivalent ligands provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:181429 USPATFULL

TITLE: METHODS AND REAGENTS FOR REGULATION OF CELLULAR RESPONSES IN BIOLOGICAL SYSTEMS

INVENTOR(S): Kiessling, Laura L., Dr., 2320 Lakeland Avenue,  
Madison, WI, UNITED STATES 53704  
Strong, Laura E., Dr., 4403 Dwight Drive, Madison,



WI, UNITED STATES 53706  
Gestwicki , Jason E. , Dr., 15 Sherman Terrace #6,  
Madison, WI, UNITED STATES 53704  
PATENT ASSIGNEE(S): WISCONSIN ALUMNI RESEARCH FOUNDATION, MADISON,  
53707-7365, WI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003125262	A1	20030703
APPLICATION INFO.:	US 2001-815296	A1	20010321 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-60191014	20000321
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GREENLEE, WINNER & SULLIVAN, Sally A. Sullivan, 5370 Manhattan Circle , Suite 201, Boulder, CO, 80303	
NUMBER OF CLAIMS:	141	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	2883	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN,  
CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITIS  
L4 95 S L2 AND L1  
L5 2524 S F-MET-LEU  
L6 346 S N-FORMYL PEPTIDES  
L7 0 S L6 AND L1  
L8 1 S L5 AND L1  
L9 19 S L5 AND L6  
L10 365786 S FIBROSIS  
L11 0 S L10 AND VAS DEFERENS REPAIR  
L12 1 S L10 AND FALLOPIAN TUBE REPAIR  
L13 109111 S L10 AND THERAPY  
L14 1 S L13 AND L6

=>

=> s antifibrotic peptide  
L15 8 ANTIFIBROTIC PEPTIDE

=> s N-formyl-methionyl-leucyl  
L16 5176 N-FORMYL-METHIONYL-LEUCYL

=> s l16 and l10  
L17 56 L16 AND L10

=> d l17 ti abs ibib 1-30

L17 ANSWER 1 OF 56 MEDLINE on STN  
TI Mesothelial cell transplantation in models of acute inflammation and  
chronic peritoneal dialysis.

AB OBJECTIVES: Mesothelial cell (MC) injury caused by continuous exposure to unphysiological peritoneal dialysis (PD) fluid and by episodes of peritonitis can eventually lead to peritoneal adhesions and peritoneal fibrosis. In the present study, we evaluated the possibility of using autologous genetically modified MCs for transplantation after the induction of peritoneal injury by acute inflammatory mediators or chronic instillation of PD fluid. METHODS: Rats were injected intraperitoneally either once with N-formyl-methionyl-leucyl-phenylalanine (fMLP), or thioglycollate, or PD fluid (i.e., Dianeal (Baxter Healthcare, Deerfield, Illinois, USA) or Physioneal (Baxter, Nivelles, Belgium)], or chronically (up to 8 weeks) with Dianeal. From 2 to 48 hours later, animals were injected with syngeneic MCs genetically modified to express the LacZ reporter gene. Rats were sacrificed 2 days later and expression of beta-galactosidase (beta-Gal) was visualized by X-Gal staining of excised tissues. Quantification of the percent area of beta-Gal-positive MCs on part of the parietal peritoneum was performed using computerized image analysis. RESULTS: The highest numbers of repopulated genetically modified MCs were observed 8 hours after a single thioglycollate injection, approximately 0.66% of a representative 2-cm<sup>2</sup> area selected for study (corresponding to approximately 10% of the peritoneal surface). The number of genetically modified MCs found to repopulate the peritoneal surface following short-term injury varied with inflammatory mediator (thioglycollate > PD fluid > fMLP) and duration of exposure. No obvious differences were observed between the two PD fluids tested. Reimplantation of syngeneic genetically modified MCs was also observed after chronic instillation of PD fluid. CONCLUSIONS: These data demonstrate that transplanted genetically modified MCs repopulate the denuded areas on the peritoneal surface that were caused by acute or chronic inflammation. This technique opens possibilities of MC transplantation and gene therapy in order to prevent complications relevant to the continuous ambulatory PD setting.

ACCESSION NUMBER: 2003428106 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 12968839  
TITLE: Mesothelial cell transplantation in models of acute inflammation and chronic peritoneal dialysis.  
AUTHOR: Hekking Liesbeth H P; Harvey V Susan; Havenith Carin E G; van den Born Jacob; Beelen Robert H J; Jackman Robert W; Nagy Janice A  
CORPORATE SOURCE: Department of Molecular Cell Biology, VU University Medical Center, Amsterdam, The Netherlands..  
ehp.hekking.cell@med.vu.nl  
SOURCE: Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis, (2003 Jul-Aug) 23 (4) 323-30.  
Journal code: 8904033. ISSN: 0896-8608.  
PUB. COUNTRY: Canada  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200401  
ENTRY DATE: Entered STN: 20030913  
Last Updated on STN: 20040130  
Entered Medline: 20040129

L17 ANSWER 2 OF 56 MEDLINE on STN

TI Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction.

AB This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction. The renal failure markers monitored were the extent of renal interstitial fibrosis and that of macrophage infiltration. In kidneys with unilateral ureteral obstruction, interstitial fibrosis was observed, using Sirius-Red staining, on day 16 after unilateral ureteral obstruction. Macrophage infiltration

was observed by immunohistochemistry, using the antibody, ED1. Interstitial **fibrosis** and macrophage infiltration were significantly attenuated in fasudil-treated animals. The migration of monocytes in vitro elicited by **N-formyl-methionyl-leucyl-phenylalanine** was potently inhibited by fasudil and its active metabolite, hydroxyfasudil. These results suggest that inhibition of Rho-kinase produces a reduction of macrophage infiltration and represents a new therapeutic strategy for renal **fibrosis**, a major factor in the progression to end-stage renal failure.

Copyright 2002 Elsevier Science B.V.

ACCESSION NUMBER: 2002687732 MEDLINE  
DOCUMENT NUMBER: 22335807 PubMed ID: 12445583  
TITLE: Fasudil attenuates interstitial **fibrosis** in rat kidneys with unilateral ureteral obstruction.  
AUTHOR: Satoh Shin-ichi; Yamaguchi Tamami; Hitomi Asako; Sato Norihiro; Shiraiwa Kazumi; Ikegaki Ichiro; Asano Toshio; Shimokawa Hiroaki  
CORPORATE SOURCE: Institute of Life Science Research, Asahi Kasei Corporation, 632-1, Mifuku, Ohito-Cho, Tagata-Gun, Shizuoka 410-2321, Japan.. sato.sn@om.asahi-kasei.co.jp  
SOURCE: EUROPEAN JOURNAL OF PHARMACOLOGY, (2002 Nov 29) 455 (2-3) 169-74.  
Journal code: 1254354. ISSN: 0014-2999.  
PUB. COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 200305  
ENTRY DATE: Entered STN: 20021214  
Last Updated on STN: 20030517  
Entered Medline: 20030516

L17 ANSWER 3 OF 56 MEDLINE on STN

TI Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone.

AB Erythema elevatum diutinum (EED) is a type of leucocytoclastic vasculitis of unknown aetiology. We report a patient with unusually widespread and disabling EED that had been unresponsive to corticosteroids and antibiotics, but resolved on dapsone. Biopsies of fresh lesions showed typical features of leucocytoclastic vasculitis, with prominent neutrophil infiltration, marked expression of the beta(2)-integrins CR3 and LFA-1, and increased mast cell numbers. Older lesions exhibited granulation tissue and **fibrosis**, macrophages were more dominant, beta(2)-integrins were expressed less markedly, and mast cell numbers were lower. In vitro chemotaxis of the patient's peripheral blood neutrophils prior to treatment showed increased random migration and directed migration towards interleukin-8 (by 424%), but a profoundly decreased responsiveness towards the bacterial peptide analogue **N-formyl-methionyl-leucyl-phenylalanine** (fMLP) (by 98%). These values returned to normal after dapsone treatment and clinical improvement 5 months later. These findings support the concept that in EED, activation via cytokines such as interleukin-8 allows a selective recruitment of leucocytes to tissue sites, while immune complexes and bacterial peptides sustain the persistent local inflammatory infiltrate and the leucocytoclastic vasculitis.

ACCESSION NUMBER: 2000424563 MEDLINE  
DOCUMENT NUMBER: 20408681 PubMed ID: 10951156  
TITLE: Erythema elevatum diutinum--evidence for disease-dependent leucocyte alterations and response to dapsone.  
AUTHOR: Grabbe J; Haas N; Moller A; Henz B M  
CORPORATE SOURCE: Department of Dermatology, Medical University of Luebeck, Ratzenburger Allee 160, D-23538 Luebeck, Germany.  
SOURCE: BRITISH JOURNAL OF DERMATOLOGY, (2000 Aug) 143 (2) 415-20.

Journal code: 0004041. ISSN: 0007-0963.  
 PUB. COUNTRY: ENGLAND: United Kingdom  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200009  
 ENTRY DATE: Entered STN: 20000922  
 Last Updated on STN: 20000922  
 Entered Medline: 20000914

L17 ANSWER 4 OF 56 MEDLINE on STN

TI Altered intracellular pH regulation in neutrophils from patients with cystic **fibrosis**.

AB Cystic **fibrosis** (CF) is a condition characterized by neutrophil-mediated lung damage and bacterial colonization. The physiological basis for reported functional alterations in CF neutrophils, including increased release of neutrophil elastase, myeloperoxidase, and oxidants, is unknown. These processes are, however, regulated by intracellular pH (pH(i)). We demonstrate here that pH(i) regulation is altered in neutrophils from CF patients. Although resting pH(i) is similar, pH(i) after acid loading and activation (N-formyl-methionyl-leucyl-phenylalanine and phorbol 12-myristate 13-acetate) is more acidic in CF cells than in normal cells. Furthermore, patients with non-CF-related bronchiectasis handle acid loading and activation in a fashion similar to subjects with normal neutrophils, suggesting that chronic pulmonary inflammation alone does not explain the difference in pH(i). This is further supported by data showing that normal neutrophils exposed to the CF pulmonary milieu respond by increasing pH(i) as opposed to decreasing pH(i) as seen in activated CF neutrophils. These pH(i) differences in activated or acid-loaded CF neutrophils are abrogated by ZnCl(2) but not by amiloride and bafilomycin A(1), suggesting that passive proton conductance is abnormal in CF. In addition, DIDS, which inhibits HCO(3)(-)/Cl(-) exchange, causes alkalinization of control but not of CF neutrophils, suggesting that anion transport is also abnormal in CF neutrophils. In summary, we have shown that pH(i) regulation in CF neutrophils is intrinsically abnormal, potentially contributing to the pulmonary manifestations of the condition.

ACCESSION NUMBER: 2000386236 MEDLINE  
 DOCUMENT NUMBER: 20351811 PubMed ID: 10893204  
 TITLE: Altered intracellular pH regulation in neutrophils from patients with cystic **fibrosis**.  
 AUTHOR: Coakley R J; Taggart C; Canny G; Greally P; O'Neill S J; McElvaney N G  
 CORPORATE SOURCE: Pulmonary Research Division, Beaumont Hospital, Dublin 9, Ireland.  
 SOURCE: AMERICAN JOURNAL OF PHYSIOLOGY. LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, (2000 Jul) 279 (1) L66-74.  
 Journal code: 100901229. ISSN: 1040-0605.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Priority Journals  
 ENTRY MONTH: 200008  
 ENTRY DATE: Entered STN: 20000818  
 Last Updated on STN: 20000818  
 Entered Medline: 20000808

L17 ANSWER 5 OF 56 MEDLINE on STN

TI Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis.

AB Human neutrophils contain three isoforms of antimicrobial and cytotoxic peptides in the azurophil granules, which belong to a family of mammalian neutrophil peptides named defensins. Here we investigate the role of these peptides in diffuse panbronchiolitis (DPB). Defensins (human

neutrophil peptide-1, -2 and -3) were measured by radioimmunoassay in bronchoalveolar lavage fluid (BALF) of 30 patients with DPB, 16 patients with idiopathic pulmonary fibrosis (IPF) and 15 healthy adults. The concentration of defensins was higher in BALF of patients with DPB than in patients with IPF and healthy subjects. DPB and IPF patients also had significantly higher plasma concentrations of defensins than controls. In patients with DPB, BALF concentration of defensins correlated significantly with neutrophil count or BALF concentration of interleukin (IL)-8. Immunohistochemistry of open-lung biopsy specimens from four DPB patients showed localization of defensins in neutrophils and mucinous exudate in the airways, and on the surface of bronchiolar epithelial cells. In vitro studies showed an enhanced extracellular release of defensins following stimulation of neutrophils with phorbol myristate acetate, N-formyl-methionyl-leucyl-phenylamine, and human recombinant IL-8. Treatment of DPB with macrolides for 6 months significantly reduced neutrophil count and concentrations of defensins and IL-8 in BALF. Our results indicate accumulation of neutrophil-derived defensins in the airway in diffuse panbronchiolitis, and suggest that defensins may be a marker of neutrophil activity in this disease.

ACCESSION NUMBER: 1998202279 MEDLINE  
DOCUMENT NUMBER: 98202279 PubMed ID: 9543278  
TITLE: Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis.  
AUTHOR: Ashitani J; Mukae H; Nakazato M; Ihi T; Mashimoto H; Kadota J; Kohno S; Matsukura S  
CORPORATE SOURCE: The Third Dept of Internal Medicine, Miyazaki Medical College, Kiyotake, Japan.  
SOURCE: EUROPEAN RESPIRATORY JOURNAL, (1998 Jan) 11 (1) 104-11. Journal code: 8803460. ISSN: 0903-1936.  
PUB. COUNTRY: Denmark  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199805  
ENTRY DATE: Entered STN: 19980520  
Last Updated on STN: 19980520  
Entered Medline: 19980514

L17 ANSWER 6 OF 56 MEDLINE on STN

TI Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.  
AB Evidence that leukotriene B4 (LTB4) is a significant inflammatory mediator in chronic pseudomonas respiratory disease was sought in adolescents and young adults with cystic fibrosis. Specific chemotaxis of peripheral blood polymorphonuclear leucocytes (PMN) was used as an indirect measure of remote in vivo exposure to LTB4. PMN from 17 patients showed a significant decrease in chemotaxis to 10(-7)-10(-9) M LTB4, but normal responses to 10(-8) M n-formyl-methionyl-leucyl-phenylalanine and 4 mg/ml casein, when compared with 17 healthy age- and sex-matched controls. This result is consistent with chronic production of LTB4, and specific deactivation of circulating PMN receptors for LTB4 in patients with cystic fibrosis. Pharmacologic inhibition of LTB4 production in vivo may help elucidate its role in the pathogenesis of lung damage in cystic fibrosis.

ACCESSION NUMBER: 92346910 MEDLINE  
DOCUMENT NUMBER: 92346910 PubMed ID: 1322257  
TITLE: Decreased polymorphonuclear leucocyte chemotactic response to leukotriene B4 in cystic fibrosis.  
AUTHOR: Lawrence R H; Sorrelli T C  
CORPORATE SOURCE: Centre for Infectious Diseases and Microbiology, Westmead Hospital, NSW, Australia.  
SOURCE: CLINICAL AND EXPERIMENTAL IMMUNOLOGY, (1992 Aug) 89 (2)

321-4.  
Journal code: 0057202. ISSN: 0009-9104.  
PUB. COUNTRY: ENGLAND: United Kingdom  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199209  
ENTRY DATE: Entered STN: 19920911  
Last Updated on STN: 19920911  
Entered Medline: 19920901

L17 ANSWER 7 OF 56 MEDLINE on STN

TI Increased whole blood chemiluminescence in patients with Shwachman syndrome: therapy trial with thiamine and alpha-tocopherol.  
AB Neutrophils purified from peripheral blood of patients with the Shwachman syndrome show enhanced chemiluminescence (CL) and depressed chemotaxis. Here we present data showing that the increased CL response can be demonstrated by using a whole blood CL assay. This assay is well-suited for studies in infants, because the blood sample volumes needed are small. Increase in CL was most distinct in the initial (1 min) activation induced by **N-formyl-methionyl-leucyl-phenylalanine**. The 1-min response is considered to derive from extracellular production of oxygen radicals. Such an extracellular oxygen radical production may render the patients susceptible to undue oxidant stress. We therefore treated the patients with two antioxidants, thiamine and alpha-tocopherol, for 3 months. This supplementation, however, failed to exert any significant effect on either whole blood CL or migration of the patients' neutrophils under agarose.

ACCESSION NUMBER: 91257060 MEDLINE  
DOCUMENT NUMBER: 91257060 PubMed ID: 2044587  
TITLE: Increased whole blood chemiluminescence in patients with Shwachman syndrome: therapy trial with thiamine and alpha-tocopherol.  
AUTHOR: Ristola M; Savilahti E; Leirisalo-Repo M; Repo H  
CORPORATE SOURCE: Department of Bacteriology and Immunology, University of Helsinki, Finland.  
SOURCE: EUROPEAN JOURNAL OF PEDIATRICS, (1991 Jan) 150 (3) 173-8.  
Journal code: 7603873. ISSN: 0340-6199.  
PUB. COUNTRY: GERMANY: Germany, Federal Republic of  
DOCUMENT TYPE: (CLINICAL TRIAL)  
Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199107  
ENTRY DATE: Entered STN: 19910802  
Last Updated on STN: 19910802  
Entered Medline: 19910717

L17 ANSWER 8 OF 56 MEDLINE on STN

TI Increased phagocytic cell chemiluminescence in patients with cystic **fibrosis**.  
AB The oxidative burst of polymorphonuclear cells and monocytes from patients with cystic **fibrosis** as measured by luminol-enhanced chemiluminescence was examined after in vitro activation of the cells. All patients were outpatients at the time of the assays; their median age was 25.5 years (range, 12 to 33 years) and normal controls were young healthy adults. Stimulation of polymorphonuclear cells with phorbol myristate acetate, the chemotactic peptide **N-formyl-methionyl-leucyl-phenylalanine**, and the calcium ionophore A23187 resulted in significantly greater chemiluminescence responses from the cells of patients than from the control cells. The monocyte response of patients to opsonized zymosan was also greater than that of controls. Thus, phagocytic cells from adolescents and young adults with cystic **fibrosis** have a greater chemiluminescence

response to a variety of stimuli. This may result in tissue damage in the lungs of these patients and thus make them more susceptible to pulmonary infections.

ACCESSION NUMBER: 89333629 MEDLINE  
DOCUMENT NUMBER: 89333629 PubMed ID: 2502909  
TITLE: Increased phagocytic cell chemiluminescence in patients with cystic **fibrosis**.  
AUTHOR: Roberts R L; Stiehm E R  
CORPORATE SOURCE: UCLA Cystic Fibrosis Research Center.  
SOURCE: AMERICAN JOURNAL OF DISEASES OF CHILDREN, (1989 Aug) 143 (8) 944-50.  
Journal code: 0370471. ISSN: 0002-922X.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 198909  
ENTRY DATE: Entered STN: 19900309  
Last Updated on STN: 19900309  
Entered Medline: 19890901

L17 ANSWER 9 OF 56 MEDLINE on STN

TI Alteration of the **N-formyl-methionyl-leucyl**-phenylalanine-induced response in cystic **fibrosis** neutrophils.

AB In order to determine whether cystic **fibrosis** neutrophils are affected in their secretory functions, lysosomal enzyme release and chemiluminescence (light emission from cells) were assayed in patients' cells and compared with those in normal control cells. We observed a decreased response of cystic **fibrosis** neutrophils in beta-glucuronidase release and chemiluminescence after stimulation by **N-formyl-methionyl-leucyl**-phenylalanine. There was no significant correlation of these results with the clinical score nor with the medical treatment. On the other hand, responses to the calcium ionophore A23187 and to opsonized zymosan showed no significant difference between normal and cystic **fibrosis** subjects in lysosomal enzyme release. **N-formyl-methionyl-leucyl**-phenylalanine receptor alterations did not seem involved in the observed effect as demonstrated by Scatchard plot analysis of **N-formyl-methionyl-leucyl**-phenylalanine binding to these receptors. These results clearly demonstrate a difference between normal and cystic **fibrosis** neutrophils in release and chemiluminescence responses to **N-formyl-methionyl-leucyl**-phenylalanine stimulation, a difference that might be located in the plasma membrane as both responses are membrane dependent.

ACCESSION NUMBER: 86232319 MEDLINE  
DOCUMENT NUMBER: 86232319 PubMed ID: 3086828  
TITLE: Alteration of the **N-formyl-methionyl-leucyl**-phenylalanine-induced response in cystic **fibrosis** neutrophils.  
AUTHOR: Kemp T; Schram-Doumont A; van Geffel R; Kram R; Szpirer C  
SOURCE: PEDIATRIC RESEARCH, (1986 Jun) 20 (6) 520-6.  
Journal code: 0100714. ISSN: 0031-3998.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 198606  
ENTRY DATE: Entered STN: 19900321  
Last Updated on STN: 19970203  
Entered Medline: 19860627

L17 ANSWER 10 OF 56 USPATFULL on STN

TI Immune-modulating peptide  
AB Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:319238 USPATFULL  
TITLE: Immune-modulating peptide  
INVENTOR(S): Ryu, Sung-Ho, Pohang-city, KOREA, REPUBLIC OF  
Suh, Pann-Ghill, Pohang-city, KOREA, REPUBLIC OF  
Bae, Yoe-Sik, Pohang-city, KOREA, REPUBLIC OF  
Song, Ji-Young, Pohang-city, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003224987	A1	20031204
APPLICATION INFO.:	US 2003-353419	A1	20030129 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-352930P	20020129 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BAKER & BOTTS, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1442	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 11 OF 56 USPATFULL on STN

TI Compositions and methods for detecting protein modification and enzymatic activity  
AB This invention relates generally to the field of protein modification, e.g., post-translational modification. In particular, the invention provides a method for detecting protein modification profile in a sample, which method comprises: a) contacting a sample containing or suspected of containing a target protein with a capture molecule, or a plurality of capture molecules, immobilized on a solid support, said capture molecule is capable of specifically binding to said target protein, whereby said target protein is immobilized on said solid support; and b) assessing modification status and/or identity of said immobilized target protein. Kits and arrays useful for detecting protein modification are also provided. Arrays, kits and methods useful for detecting enzymatic activities, especially protein modification enzymatic activities, are further provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:219724 USPATFULL  
TITLE: Compositions and methods for detecting protein modification and enzymatic activity  
INVENTOR(S): Shen, Li, Potomac, MD, UNITED STATES  
Cen, Hui, Oakland, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------



PATENT INFORMATION: US 2003153014 A1 20030814  
 APPLICATION INFO.: US 2003-356442 A1 20030130 (10)  
 RELATED APPLN. INFO.: Division of Ser. No. US 2000-678644, filed on 3 Oct 2000, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158560P	19991008 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Peng Chen, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332	
NUMBER OF CLAIMS:	52	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	2570	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 12 OF 56 USPATFULL on STN

TI Preventing airway mucus production by administration of EGF-R antagonists  
 AB Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:214347 USPATFULL  
 TITLE: Preventing airway mucus production by administration of EGF-R antagonists  
 INVENTOR(S): Nadel, Jay A., San Francisco, CA, UNITED STATES  
 Takeyama, Kiyoshi, Tokyo, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003148990	A1	20030807
APPLICATION INFO.:	US 2003-359932	A1	20030207 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-865239, filed on 24 May 2001, GRANTED, Pat. No. US 6551989 Continuation of Ser. No. US 2001-794232, filed on 26 Feb 2001, GRANTED, Pat. No. US 6566324 Continuation of Ser. No. US 1999-375597, filed on 17 Aug 1999, GRANTED, Pat. No. US 6270747		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97023P	19980818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2620	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 13 OF 56 USPATFULL on STN

TI Small peptides and methods for treatment of asthma and inflammation  
AB A pharmaceutical composition is described as an admixture of a pharmacological carrier and a peptide having the formula f-Met-Leu-X. X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. Also described are methods for inhibiting the degranulation of mast cells and for treating inflammation in a patient, for example, where the inflammation is a result of a disease selected from the group consisting of asthma, rheumatoid arthritis and anaphylaxis. In addition, methods are described for inhibiting the release of cytokines in a patient, for inhibiting the release of histamines in a patient, for inhibiting the release leukotrienes in a patient, for reducing adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation in a patient, for reducing the production of IgE antibodies at site of inflammation in a patient, and for inhibiting increased vascular permeability at site of inflammation in a patient. The methods use the described pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:188407 USPATFULL  
TITLE: Small peptides and methods for treatment of asthma and inflammation  
INVENTOR(S): Houck, John C., Seattle, WA, UNITED STATES  
MacDonald, Mary, Lynden, WA, UNITED STATES LR  
PATENT ASSIGNEE(S): Hisatek, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003130200	A1	20030710
APPLICATION INFO.:	US 2002-192000	A1	20020709 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-189130, filed on 10 Nov 1998, GRANTED, Pat. No. US 6462020		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-65336P	19971113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS & ANGELL, LLP, P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	14 Drawing Page(s)	
LINE COUNT:	1469	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 14 OF 56 USPATFULL on STN

TI Therapeutics for chemokine mediated diseases  
AB The invention provides therapeutic and biological uses of chemokine-receptor-binding compounds (including chemokine receptor ligands such as chemokine receptor agonists or antagonists), such as tricyclic phenanthrene derivatives, including uses in the treatment of disease states mediated by chemokines. The relevant chemokines may for example be monocyte chemoattractant protein-one (MCP-1) or interleukin-8 (IL-8), and the relevant chemokine receptors may for example be corresponding chemokine receptors (CCR-2, CCR-4, CXCR-1, and CXCR-2). In other aspects, the invention provides corresponding pharmaceutical compositions and therapeutic methods. In one aspect, for example, the invention provides for the use of phenanthrene-9,10-dione in the treatment of multiple sclerosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:100154 USPATFULL  
TITLE: Therapeutics for chemokine mediated diseases  
INVENTOR(S): Saxena, Geeta, Vancouver, CANADA  
Tudan, Christopher R., Vancouver, CANADA

Salari, Hassan, Delta, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069265	A1	20030410
APPLICATION INFO.:	US 2001-767378	A1	20010122 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	CA 2000-2330350	20001206
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025	
NUMBER OF CLAIMS:	30	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1382	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 15 OF 56 USPATFULL on STN

TI Immune-enhancing peptides  
AB Disclosed are peptides having SEQ ID NOs: 1 to 32 that can stimulate superoxide generation in human monocytes. Superoxide is the most important armory on the primary defense line of monocytes against invading pathogens, and the identification of new stimuli and the characterization of the regulatory mechanism of superoxide generation are of paramount importance.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:79074 USPATFULL  
TITLE: Immune-enhancing peptides  
INVENTOR(S): Bae, Hyun-Joo, Daegu, KOREA, REPUBLIC OF  
Bae, Yoe-Sik, Koryung-gun, KOREA, REPUBLIC OF  
Kim, Youn-Dong, Pohang-si, KOREA, REPUBLIC OF  
Cho, Eun-Jung, Pusan, KOREA, REPUBLIC OF  
Kim, Jong-In, Pohang-si, KOREA, REPUBLIC OF  
Lee, Tae-Hoon, Pohang-si, KOREA, REPUBLIC OF  
Suh, Pann-Ghill, Pohang-si, KOREA, REPUBLIC OF  
Ryu, Sung Ho, Pohang-si, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003055001	A1	20030320
APPLICATION INFO.:	US 2002-186035	A1	20020628 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302744P	20010703 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	David A. Einhorn, Esq., Anderson Kill & Olick, P.C., 1251 Avenue of the Americas, New York, NY, 10020	
NUMBER OF CLAIMS:	86	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1619	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 16 OF 56 USPATFULL on STN

TI Small peptides and methods for treatment of asthma and inflammation  
AB Methods for treating allergies, cutaneous inflammation, arthritis, chronic obstruction pulmonary disease and treating chronic inflammatory bowel disease are described. Also described is a method for inhibiting

the infiltration of eosinophils into airways of a patient, a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:17906 USPATFULL  
TITLE: Small peptides and methods for treatment of asthma and inflammation  
INVENTOR(S): Houck, John C., Seattle, WA, UNITED STATES  
Clagett, James, Snohomish, WA, UNITED STATES  
PATENT ASSIGNEE(S): Hisatek, LLC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003013658	A1	20030116
APPLICATION INFO.:	US 2002-147633	A1	20020516 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-190043, filed on 10 Nov 1998, GRANTED, Pat. No. US 6391856		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-65336P	19971113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DIKE, BRONSTEIN, ROBERTS AND CUSHMAN,, INTELLECTUAL PROPERTY PRACTICE GROUP, EDWARDS & ANGELL, LLP., P.O. BOX 9169, BOSTON, MA, 02209	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	1511	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 17 OF 56 USPATFULL on STN

TI Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2

AB Methods for treating or modulating inflammatory processes or chronic inflammatory conditions dependent upon cellular inflammation, such as asthma and rheumatoid arthritis are provided, as well as methods for inhibiting or blocking eosinophil migration and airway hyperresponsiveness. Also described is a method for treating or preventing the adhesion of granulocytes and other inflammatory cells into the tissue that is the site of the inflammation. In particular, the methods relate to the therapeutic or prophylactic use of compounds and compositions that inhibit cytosolic phospholipase A.sub.2.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:295074 USPATFULL  
TITLE: Method of treating inflammatory conditions by inhibiting cytosolic phospholipase A2  
INVENTOR(S): Leff, Alan, Chicago, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165119	A1	20021107
APPLICATION INFO.:	US 2002-62730	A1	20020131 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-265298P	20010131 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MERCHANT & GOULD PC, P.O. BOX 2903, MINNEAPOLIS, MN, 55402-0903	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	1069	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 18 OF 56 USPATFULL on STN

TI Small peptides and methods for treatment of asthma and inflammation  
 AB A pharmaceutical composition is described as an admixture of a pharmacological carrier and a peptide having the formula f-Met-Leu-X. X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. Also described are methods for inhibiting the degranulation of mast cells and for treating inflammation in a patient, for example, where the inflammation is a result of a disease selected from the group consisting of asthma, rheumatoid arthritis and anaphylaxis. In addition, methods are described for inhibiting the release of cytokines in a patient, for inhibiting the release of histamines in a patient, for inhibiting the release leukotrienes in a patient, for reducing adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation in a patient, for reducing the production of IgE antibodies at site of inflammation in a patient, and for inhibiting increased vascular permeability at site of inflammation in a patient. The methods use the described pharmaceutical composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:262344 USPATFULL  
 TITLE: Small peptides and methods for treatment of asthma and inflammation  
 INVENTOR(S): Houck, John C., late of Seattle, WA, United States deceased  
 MacDonald, Mary, Lynden, WA, United States executrix  
 PATENT ASSIGNEE(S): Hisatek, LLC, Seattle, WA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6462020	B1	20021008
APPLICATION INFO.:	US 1998-189130		19981110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-65336P	19971113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Borin, Michael	
LEGAL REPRESENTATIVE:	Neuner, George W., Edwards & Angell, LLP Intellectual Property Practice Group	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 18 Drawing Page(s)	
LINE COUNT:	1396	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 19 OF 56 USPATFULL on STN

TI Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases  
 AB The present invention relates to substances which modulate receptors

involved in inflammatory processes and whose modulated functions positively influence inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:221354 USPATFULL  
TITLE: Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases  
INVENTOR(S): Jung, Birgit, Schwabenheim, GERMANY, FEDERAL REPUBLIC OF  
Kraut, Norbert, Eberhardzell, GERMANY, FEDERAL REPUBLIC OF  
Mueller, Stefan, Mainz, GERMANY, FEDERAL REPUBLIC OF  
Kistler, Barbara, Pfungstadt, GERMANY, FEDERAL REPUBLIC OF  
Seither, Peter, Rissege Halde, GERMANY, FEDERAL REPUBLIC OF  
Quast, Karsten, Schemmerberg, GERMANY, FEDERAL REPUBLIC OF  
Weith, Andreas, Eberhardzell, GERMANY, FEDERAL REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119494	A1	20020829
APPLICATION INFO.:	US 2001-944807	A1	20010831 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2000-21484	20000901
	US 2000-233748P	20000919 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD, P. O. BOX 368, RIDGEFIELD, CT, 06877	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2302	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 20 OF 56 USPATFULL on STN

TI Treatment with small peptides to effect antifibrotic activity  
AB Methods for treating treating **fibrosis** in a mammal are described. An antifibrotic effective amount of a peptide having the formula f-Met-Leu-X where X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr is administered to the mammal. The **fibrosis** may be due to pathological changes resulting, e.g., from pulmonary **fibrosis**, atherosclerosis, cirrhosis, glomerulosclerosis, chronic pancreatitis, coronary artery disease (such as caused by infection by bacterium Chlamydia pneumoniae), trauma or surgical procedures. Examples of surgical procedures that cause **fibrosis** are post-operative **fibrosis** peri-neurally in the dura or nerve roots following spinal surgery, tenolysis of injured or repaired tendons with adhesions, neurolysis of damaged or repaired peripheral nerves with adhesions, post-operative adhesions from gynecologic and abdominal surgeries, reparative surgery of the vas deferens or fallopian tubes for reversal of male or female sterilization, and surgical repair of other tubular structures such as urethra, intestine or esophagus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:141513 USPATFULL  
TITLE: Treatment with small peptides to effect antifibrotic activity

INVENTOR(S) : Clagett, James, Snohomish, WA, UNITED STATES  
PATENT ASSIGNEE(S) : Histatek, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002072499	A1	20020613
APPLICATION INFO.:	US 2001-960720	A1	20010921 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2000-US7411, filed on 20 Mar 2000, UNKNOWN		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-125514P	19990322 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Edwards & Angell, LLP, P.O. Box 9169, Boston, MA, 02209	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	814	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 21 OF 56 USPATFULL on STN

TI Method for treatment of allergic reaction using formyl peptide  
AB Methods for treating allergies, cutaneous inflammation, arthritis, chronic obstruction pulmonary disease and treating chronic inflammatory bowel disease are described. Also described is a method for inhibiting the infiltration of eosinophils into airways of a patient, a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte; thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:116255 USPATFULL  
TITLE: Method for treatment of allergic reaction using formyl peptide  
INVENTOR(S) : Houck, John C., late of Seattle, WA, United States deceased  
Mary MacDonald, United States executor  
Clagett, James, Snohomish, WA, United States  
PATENT ASSIGNEE(S) : Histatek, LLC, San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6391856	B1	20020521
APPLICATION INFO.:	US 1998-190043		19981110 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-65336P	19971113 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Borin, Michael	
LEGAL REPRESENTATIVE:	Neuner, George W., Edwards & Angell, LLP	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 18 Drawing Page(s)	

LINE COUNT: 1428  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 22 OF 56 USPATFULL on STN

TI Therapeutic methods that target fractalkine or CX3CR1  
AB The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:106247 USPATFULL  
TITLE: Therapeutic methods that target fractalkine or CX3CR1  
INVENTOR(S): Koch, Alisa E., River Forest, IL, UNITED STATES  
PATENT ASSIGNEE(S): Northwestern University, Evanston, IL (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055456	A1	20020509
APPLICATION INFO.:	US 2001-789486	A1	20010220 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183568P	20000218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	2426	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 23 OF 56 USPATFULL on STN

TI Method and product for regulating apoptosis  
AB The present invention relates to isolated MEKK1 proteins, nucleic acid molecules having sequences that encode such proteins, and antibodies raised against such proteins. The present invention also includes methods to use such proteins to regulate apoptosis. The invention provides active fragments of MEKK1 proteins that are generated upon cleavage of MEKK1 with a caspase protease. These active fragments are capable of stimulating apoptosis. Moreover, the invention provides protease-resistant forms of MEKK1 proteins, that are resistant to cleavage by caspase proteases and that are capable of inhibiting apoptosis. Still further, the invention provides methods for generating an active fragment of MEKK1, methods of identifying modulators of the apoptotic activity of an active fragment of MEKK1 and methods of identifying modulators of caspase-mediated cleavage of MEKK1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:105925 USPATFULL  
TITLE: Method and product for regulating apoptosis  
INVENTOR(S): Johnson, Gary L., Boulder, CO, UNITED STATES  
PATENT ASSIGNEE(S): National Jewish Center for Immunology and Respiratory Medicine (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002055130	A1	20020509
APPLICATION INFO.:	US 2001-858754	A1	20010516 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-23130, filed on 13 Feb 1998, ABANDONED		



	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 1997-39740P	19970214 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAHIVE & COCKFIELD, 28 STATE STREET, BOSTON, MA, 02109	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	22 Drawing Page(s)	
LINE COUNT:	6845	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 24 OF 56 USPATFULL on STN

TI Therapeutic methods that target fractalkine or CX3CR1

AB The invention relates to antagonists of CX3C chemokine receptor 1 (CX3CR1) function, antagonists of fractalkine function and to therapeutic methods employing the antagonists. The invention also relates to a method for diagnosing rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:105673 USPATFULL

TITLE: Therapeutic methods that target fractalkine or CX3CR1

INVENTOR(S): Koch, Alisa E., River Forest, IL, UNITED STATES  
Ruth, Jeffrey H., Chicago, IL, UNITED STATES  
Rottman, James B., Sudbury, MA, UNITED STATES

PATENT ASSIGNEE(S): Northwestern University, Evanston, IL (U.S. corporation)

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 2002054875	A1	20020509
APPLICATION INFO.:	US 2001-789482	A1	20010220 (9)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2000-183568P	20000218 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., Two Militia Drive, Lexington, MA, 02421-4799	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	18 Drawing Page(s)	
LINE COUNT:	2520	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 25 OF 56 USPATFULL on STN

TI Preventing airway mucus production by administration of EGF-R antagonists

AB Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:205420 USPATFULL

TITLE: Preventing airway mucus production by administration of EGF-R antagonists

INVENTOR(S) : Nadel, Jay A., San Francisco, CA, United States  
Takeyama, Kiyoshi, San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001041178	A1	20011115
	US 6566324	B2	20030520
APPLICATION INFO.:	US 2001-794232	A1	20010226 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-375597, filed on 17 Aug 1999, GRANTED, Pat. No. US 6270747		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97023P	19980818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Paula A. Borden, BOZICEVIC, FIELD & FRANCIS LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2621	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L17 ANSWER 26 OF 56 USPATFULL on STN

TI Preventing airway mucus production by administration of EGF-R antagonists

AB Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:194404 USPATFULL  
TITLE: Preventing airway mucus production by administration of EGF-R antagonists  
INVENTOR(S) : Nadel, Jay A., San Francisco, CA, United States  
Takeyama, Kiyoshi, Tokyo, Japan

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036919	A1	20011101
	US 6551989	B2	20030422
APPLICATION INFO.:	US 2001-865239	A1	20010524 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-794232, filed on 26 Feb 2001, PENDING Continuation of Ser. No. US 1999-375597, filed on 17 Aug 1999, GRANTED, Pat. No. US 6270747		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97023P	19980818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PAULA A. BORDEN, Bozicevic, Field and Francis LLP, Suite 200, 200 Middlefield Road, Menlo Park, CA, 94025	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	

LINE COUNT: 2620  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 27 OF 56 USPATFULL on STN

TI In vitro and in vivo assay for agents which treat mucus hypersecretion  
AB Hypersecretion of mucus in the lungs is inhibited by the administration of an epidermal growth factor receptor (EGF-R) antagonist. The EGF-R antagonist may be in the form of a small organic molecule, an antibody, or portion of an antibody that binds to and blocks the EGF receptor. The EGF-R antagonist is preferably administered by injection in an amount sufficient to inhibit formation of goblet cells in pulmonary airways. The degranulation of goblet cells that results in airway mucus production is thereby inhibited. Assays for screening candidate agents that inhibit goblet cell proliferation are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:125533 USPATFULL  
TITLE: In vitro and in vivo assay for agents which treat mucus hypersecretion  
INVENTOR(S): Nadel, Jay A., San Francisco, CA, United States  
Takeyama, Kiyoshi, San Francisco, CA, United States  
PATENT ASSIGNEE(S): The University of California, San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6270747	B1	20010807
APPLICATION INFO.:	US 1999-375597		19990817 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97023P	19980818 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	LeGuyader, John L.	
ASSISTANT EXAMINER:	Zara, Jane	
LEGAL REPRESENTATIVE:	Borden, Paula A., Sherwood, PamelaBozicevic, Field & Francis	
NUMBER OF CLAIMS:	5	
EXEMPLARY CLAIM:	3	
NUMBER OF DRAWINGS:	9 Drawing Figure(s); 4 Drawing Page(s)	
LINE COUNT:	2604	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 28 OF 56 USPATFULL on STN

TI Pharmaceutical preparations of glutathione and methods of administration thereof  
AB A method of altering an expression of a gene product in cells or an organism, comprising orally administering glutathione in an effective amount and under such conditions to alter a redox potential in the cells. The gene expression may be sensitive to redox potential through one or more of a process of induction, transcription, translation, post-translational modification, release, and/or through a receptor mediated process. The glutathione is preferably administered as an oral bolus of encapsulated pharmaceutically stabilized glutathione in a rapidly dissolving formulation to a mammal on an empty stomach.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:40462 USPATFULL  
TITLE: Pharmaceutical preparations of glutathione and methods of administration thereof  
INVENTOR(S): Demopoulos, Harry B., Scarsdale, NY, United States  
Seligman, Myron L., Fairfield, CT, United States  
PATENT ASSIGNEE(S): Antioxidant Pharmaceuticals Corp., Elmsford, NY, United

States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6204248	B1	20010320
APPLICATION INFO.:	US 1999-457642		19991209 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-34101P	19961231 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Reamer, James H.	
LEGAL REPRESENTATIVE:	Milde, Hoffberg & Macklin, LLP	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	5144	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 29 OF 56 USPATFULL on STN

TI (R)-2-(3-benzoylphenyl) propionic acid salts and pharmaceutical preparations containing them

AB A new use of the enantiomer (R)-ketoprofen and of its salts with suitable organic and inorganic bases in the therapy of neutrophil-dependent diseases and phlogistic processes is described as well as pharmaceutical preparations containing such compounds and useful for oral, parenteral or topical administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2000:67761 USPATFULL

TITLE: (R)-2-(3-benzoylphenyl) propionic acid salts and pharmaceutical preparations containing them

INVENTOR(S): Bertini, Riccardo, Poggio Piceaze, Italy  
Bizzarri, Cinzia, L'Aquila, Italy  
Brandolini, Laura, L'Aquila, Italy  
Melillo, Gabriella, Milan, Italy  
Caselli, Gianfranco, Milan, Italy  
Clavenna, Gaetano, L'Aquila, Italy

PATENT ASSIGNEE(S): Dompe' SpA, L'Aquila, Italy (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6069172		20000530
APPLICATION INFO.:	US 1999-237901		19990127 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1998-MI146	19980128
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	MacMillan, Keith D.	
ASSISTANT EXAMINER:	Kim, Vickie	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland, and Naughton	
NUMBER OF CLAIMS:	24	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Figure(s); 2 Drawing Page(s)	
LINE COUNT:	724	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L17 ANSWER 30 OF 56 USPATFULL on STN

TI Microassay system for assessing transmigration of PMN across epithelia

in a serosal-to-mucosal direction  
AB A microassay system for the analysis of polymorphonuclear leukocyte transmigration across epithelia in the physiological direction. This assay also allows for the rapid analysis of a series of monolayers.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 95:92715 USPATFULL  
TITLE: Microassay system for assessing transmigration of PMN across epithelia in a serosal-to-mucosal direction  
INVENTOR(S): Madara, James L., Winchester, MA, United States  
PATENT ASSIGNEE(S): Brigham and Women's Hospital, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5459068		19951017
APPLICATION INFO.:	US 1993-152898		19931117 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-748349, filed on 22 Aug 1991, now abandoned which is a continuation-in-part of Ser. No. US 1991-677388, filed on 1 Apr 1991, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Beisner, William H.		
LEGAL REPRESENTATIVE:	Sterne, Kessler, Goldstein & Fox		
NUMBER OF CLAIMS:	9		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	21 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1883		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN, CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITIS  
L4 95 S L2 AND L1  
L5 2524 S F-MET-LEU  
L6 346 S N-FORMYL PEPTIDES  
L7 0 S L6 AND L1  
L8 1 S L5 AND L1  
L9 19 S L5 AND L6  
L10 365786 S FIBROSIS  
L11 0 S L10 AND VAS DEFERENS REPAIR  
L12 1 S L10 AND FALLOPIAN TUBE REPAIR  
L13 109111 S L10 AND THERAPY  
L14 1 S L13 AND L6  
L15 8 S ANTIFIBROTIC PEPTIDE  
L16 5176 S N-FORMYL-METHIONYL-LEUCYL  
L17 56 S L16 AND L10

=> d l17 ti abs 40-56

L17 ANSWER 40 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.  
AB Excessive accumulation of active neutrophil elastase (NE) in pulmonary

fluids and tissues of patients with cystic **fibrosis** (CF) is thought to act on the lungs, compromising their structure and function. The aim of this study was to investigate the in vitro and in vivo protective effect of a new, rapidly acting, potent ( $K_i = 5.45 \times 10^{-12}$  M and  $K_{on} = 8 \times 10^6$  M<sup>-1</sup> s<sup>-1</sup>) and specific human NE inhibitor, EPI-HNE-4, engineered from the Kunitz domain. The results demonstrated that this inhibitor was able to (i) effectively inhibit in vitro the high levels of active NE present in a medium as complex as sputum from children with CF, with a measured IC<sub>50</sub> equal or close to the calculated IC<sub>50</sub> in 60% of cases, and (ii) almost completely block (91%) the N-formyl-methionine-leucine-phenylalanine-induced migration of purified human neutrophils across a Matrigel basement membrane. Intratracheal administration (250, 175, or 100 µg per rat) of the inhibitor 5 min before instillation of pure human NE (HNE) (150 µg per rat) to rats induced effective, dose-dependent protection of the lungs, 4 h later, from hemorrhage, serum albumin leakage, residual active NE, and discrete neutrophil influx in air spaces induced by instillation of pure HNE. Intravenous administration (3 mg per rat) of EPI-HNE-4, 15 min before instillation of the soluble fraction of pooled sputum (delivering 120 µg of active NE per rat) from children with CF, effectively reduced (64%), 4 h later, the massive neutrophil influx induced by sputum instillation. Overall, these data strongly suggest that associated aerosol and systemic administration of EPI-HNE-4 would be beneficial in the treatment of CF.

L17 ANSWER 41 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Lipid and fatty acid imbalance and neutrophil function in cystic **fibrosis**.

L17 ANSWER 42 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Erythema elevatum diutinum: Evidence for disease-dependent leucocyte alterations and response to dapsone.

AB Erythema elevatum diutinum (EED) is a type of leucocytoclastic vasculitis of unknown aetiology. We report a patient with unusually widespread and disabling EED that had been unresponsive to corticosteroids and antibiotics, but resolved on dapsone. Biopsies of fresh lesions showed typical features of leucocytoclastic vasculitis, with prominent neutrophil infiltration, marked expression of the beta2-integrins CR3 and LFA-1, and increased mast cell numbers. Older lesions exhibited granulation tissue and **fibrosis**, macrophages were more dominant, beta2-integrins were expressed less markedly, and mast cell numbers were lower. In vitro chemotaxis of the patient's peripheral blood neutrophils prior to treatment showed increased random migration and directed migration towards interleukin-8 (by 424%), but a profoundly decreased responsiveness towards the bacterial peptide analogue N-formyl-methionyl-leucyl-phenylalanine (fMLP) (by 98%). These values returned to normal after dapsone treatment and clinical improvement 5 months later. These findings support the concept that in EED, activation via cytokines such as interleukin-8 allows a selective recruitment of leucocytes to tissue sites, while immune complexes and bacterial peptides sustain the persistent local inflammatory infiltrate and the leucocytoclastic vasculitis.

L17 ANSWER 43 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Altered intracellular pH regulation in neutrophils from patients with cystic **fibrosis**.

AB Cystic **fibrosis** (CF) is a condition characterized by neutrophil-mediated lung damage and bacterial colonization. The physiological basis for reported functional alterations in CF neutrophils, including increased release of neutrophil elastase, myeloperoxidase, and oxidants, is unknown. These processes are, however, regulated by intracellular pH (pHi). We demonstrate here that pHi regulation is altered in neutrophils from CF patients. Although resting pHi is similar, pHi after acid loading and activation (N-formyl-methionyl-leucyl-phenylalanine and phorbol 12-myristate

13-acetate) is more acidic in CF cells than in normal cells. Furthermore, patients with non-CF-related bronchiectasis handle acid loading and activation in a fashion similar to subjects with normal neutrophils, suggesting that chronic pulmonary inflammation alone does not explain the difference in pHi. This is further supported by data showing that normal neutrophils exposed to the CF pulmonary milieu respond by increasing pHi as opposed to decreasing pHi as seen in activated CF neutrophils. These pHi differences in activated or acid-loaded CF neutrophils are abrogated by ZnCl<sub>2</sub> but not by amiloride and bafilomycin A1, suggesting that passive proton conductance is abnormal in CF. In addition, DIDS, which inhibits HCO<sub>3</sub><sup>-</sup>/Cl<sup>-</sup> exchange, causes alkalization of control but not of CF neutrophils, suggesting that anion transport is also abnormal in CF neutrophils. In summary, we have shown that pHi regulation in CF neutrophils is intrinsically abnormal, potentially contributing to the pulmonary manifestations of the condition.

- L17 ANSWER 44 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Cystic **fibrosis** transmembrane conductance regulator does not affect neutrophil migration across cystic **fibrosis** airway epithelial monolayers.  
 AB Recent studies have shown that airway inflammation dominated by neutrophils, ie, polymorphonuclear cells (PMN) was observed in infants and children with cystic **fibrosis** (CF) even in the absence of detectable infection. To assess whether there is a CF-related anomaly of PMN migration across airway epithelial cells, we developed an in vitro model of chemotactic migration across tight and polarized CF15 cells, a CF human nasal epithelial cell line, seeded on porous filters. To compare PMN migration across a pair of CF and control monolayers in the physiological direction, inverted CF15 cells were infected with increasing concentrations of recombinant adenoviruses containing either the normal cystic **fibrosis** transmembrane conductance regulator (CFTR) cDNA, the DELTA508 CFTR cDNA, or the beta-galactosidase gene. The number of PMN migrating in response to N-formyl-Met-Leu-Phe across inverted CF15 monolayers expressing beta-galactosidase was similar to that seen across CF15 monolayers rescued with CFTR, whatever the proportion of cells expressing the transgene. Moreover, PMN migration across monolayers expressing various amounts of mutated CFTR was not different from that observed across matched counterparts expressing normal CFTR. Finally, PMN migration in response to adherent or *Pseudomonas aeruginosa* was equivalent across CF and corrected monolayers. The possibility that mutated CFTR may exert indirect effects on PMN recruitment, via an abnormal production of the chemotactic cytokine interleukin-8, was also explored. Apical and basolateral production of interleukin-8 by polarized CF cells expressing mutated CFTR was not different from that observed with rescued cells, either in baseline or stimulated conditions. CF15 cells displayed a CF phenotype that could be corrected by CFTR-containing adenoviruses, because two known CF defects, Cl<sup>-</sup> secretion and increased *P. aeruginosa* adherence, were normalized after infection with those viruses. Thus, we conclude that the presence of a mutated CFTR does not per se lead to an exaggerated inflammatory response of CF surface epithelial cells in the absence or presence of a bacterial infection.
- L17 ANSWER 45 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis.  
 AB Human neutrophils contain three isoforms of antimicrobial and cytotoxic peptides in the azurophil granules, which belong to a family of mammalian neutrophil peptides named defensins. Here we investigate the role of these peptides in diffuse panbronchiolitis (DPB). Defensins (human neutrophil peptide-1, -2 and -3) were measured by radioimmunoassay in bronchoalveolar lavage fluid (BALF) of 30 patients with DPB, 16 patients with idiopathic pulmonary **fibrosis** (IPF) and 15 healthy adults. The concentration of defensins was higher in BALF of patients with DPB than in patients with IPF and healthy subjects. DPB and IPF patients also

had significantly higher plasma concentrations of defensins than controls. In patients with DPB, BALF concentration of defensins correlated significantly with neutrophil count or BALF concentration of interleukin (IL)-8. Immunohistochemistry of open-lung biopsy specimens from four DPB patients showed localization of defensins in neutrophils and mucinous exudate in the airways, and on the surface of bronchiolar epithelial cells. In vitro studies showed an enhanced extracellular release of defensins following stimulation of neutrophils with phorbol myristate acetate, N-formyl-methionyl-leucyl-phenylalanine, and human recombinant IL-8. Treatment of DPB with macrolides for 6 months significantly reduced neutrophil count and concentrations of defensins and IL-8 in BALF. Our results indicate accumulation of neutrophil-derived defensins in the airway in diffuse panbronchiolitis, and suggest that defensins may be a marker of neutrophil activity in this disease.

- L17 ANSWER 46 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI G proteins as biological targets for anti-allergic drugs?  
 AB The inhibiting effect of the H-1 antihistamine cetirizine on the release of mediators (LTB-4, arachidonic acid and phospholipase A2) was measured in different cells in vitro (human PMN, DELTA-F508 cells, chinese hamster ovary cells and rabbit chondrocytes) using different agonists (fMLP, NaF, calcium ionophore A 23187, bradykinin, adrenaline and IL-1). It was shown that physiological concentrations of the drug inhibited the release when activation of receptor-coupled G proteins was involved. By contrast, there was no inhibiting effect of cetirizine when the release was induced by a calcium ionophore which bypasses the G proteins coupled to cell membrane receptors.
- L17 ANSWER 47 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI DECREASED POLYMORPHONUCLEAR LEUCOCYTE CHEMOTACTIC RESPONSE TO LEUKOTRIENE B-4 IN CYSTIC FIBROSIS.  
 AB Evidence that leukotriene B4 (LTB4) is a significant inflammatory mediator in chronic pseudomonas respiratory disease was sought in adolescents and young adults with cystic fibrosis. Specific chemotaxis of peripheral blood polymorphonuclear leucocytes (PMN) was used as an indirect measure of remote in vivo exposure to LTB4. PMN from 17 patients showed a significant decrease in chemotaxis to 10<sup>-7</sup>-10<sup>-9</sup> M LTB4, but normal responses to 10<sup>-8</sup> M n-formyl-methionyl-leucyl-phenylalanine and 4 mg/ml casein, when compared with 17 healthy age- and sex-matched controls. This results is consistent with chronic production of LTB4, and specific deactivation of circulating PMN receptors for LTB4 in patients with cystic fibrosis. Pharmacologic inhibition of LTB4 production in vivo may help elucidate its role in the pathogenesis of lung damage in cystic fibrosis.
- L17 ANSWER 48 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
 TI INCREASED PHAGOCYTIC CELL CHEMILUMINESCENCE IN PATIENTS WITH CYSTIC FIBROSIS.  
 AB The oxidative burst of polymorphonuclear cells and monocytes from patients with cystic fibrosis as measured by luminol-enhanced chemiluminescence was examined after in vitro activation of the cells. All patients were outpatients at the time of the assays; their median age was 25.5 years (range, 12 to 33 years) and normal controls were young healthy adults. Stimulation of polymorphonuclear cells with phorbol myristate acetate, the chemotactic peptide N-formyl-methionyl-leucyl-phenylalanine, and the calcium ionophore A23187 resulted in significantly greater chemiluminescence responses from the cells of patients than from the control cells. The monocyte response of patients to opsonized zymosan was also greater than that of controls. Thus, phagocytic cells from adolescents and young adults with cystic fibrosis have a greater chemiluminescence response to a variety of stimuli. This may result in tissue damage in the lungs of these patients and thus make them more susceptible to pulmonary



infections.

L17 ANSWER 49 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI ALTERATION OF THE N FORMYLMETHIONYLLEUCYLPHENYLALANINE-INDUCED RESPONSE IN  
CYSTIC FIBROSIS NEUTROPHILS.

AB In order to determine whether cystic fibrosis neutrophils are affected in their secretory functions, lysosomal enzyme release and chemiluminescence (light emission from cells) were assayed in patients' cells and compared with those in normal control cells. We observed a decreased response of cystic fibrosis neutrophils in  $\beta$ -glucuronidase release and chemiluminescence after stimulation by N-formyl-methionyl-leucyl-phenylalanine. There was no significant correlation of these results with the clinical score nor with the medical treatment. On the other hand, responses to the calcium ionophore A23187 and to opsonized zymosan showed no significant difference between normal and cystic fibrosis subjects in lysosomal enzyme release. N-formyl-methionyl-leucyl-phenylalanine receptor alterations did not seem involved in the observed effect as demonstrated by Scatchard plot analysis of N-formyl-methionyl-leucyl-phenylalanine binding to these receptors. These results clearly demonstrate a difference between normal and cystic fibrosis neutrophils in release and chemiluminescence responses to N-formyl-methionyl-leucyl-phenylalanine stimulation, a difference that might be located in the plasma membrane as both responses are membrane dependent.

L17 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils

AB Reactive oxygen species (ROS) are a common denominator of airway inflammation associated with chronic obstructive pulmonary disease (COPD) and asthma, as well as with less frequent lung diseases such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). The most frequently administered drugs used to treat these diseases are bronchodilators, antioxidant/antiphlogistic agents and mucoactive drugs. The metabolism of the mucoactive drug erdosteine produces an active metabolite (Met I) with a reducing SH group. In addition to its mucolytic action, Met I also has useful antioxidant activity. The various activities of  $\beta$ 2-agonists include their ability to reduce the respiratory burst of neutrophils and the subsequent release of ROS.  $\beta$ 2-Agonists and mucoactive drugs may be administered to the same patients during the treatment of lung diseases. The aim of this study was to investigate the ability of Met I to potentiate the activity of salbutamol in inhibiting the in vitro respiratory burst of neutrophils by means of chemiluminescence. The combination of Met I 5 and 10  $\mu$ g/mL with salbutamol  $10^{-5}$ ,  $10^{-6}$  and  $10^{-7}$  M led to a significant reduction in respiratory bursts when the neutrophils were stimulated with the soluble stimulant N-formyl-methionyl-leucyl-phenylalanine (fMLP). The combinations of the two drugs that reduced the respiratory bursts when a particulate stimulus (Candida albicans) was used were those containing  $10^{-5}$  M of salbutamol. The reasons for this different behavior remain unclear and raise questions about the specific roles, sites and mechanisms of action of the different types of stimulation undergone by the respiratory airways.

L17 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction

AB This study was designed to investigate possible effects of the Rho-kinase inhibitor, fasudil, on the progression of renal failure in rats with unilateral ureteral obstruction. The renal failure markers monitored were the extent of renal interstitial fibrosis and that of macrophage

infiltration. In kidneys with unilateral ureteral obstruction, interstitial **fibrosis** was observed, using Sirius-Red staining, on day 16 after unilateral ureteral obstruction. Macrophage infiltration was observed by immunohistochem., using the antibody, ED1. Interstitial **fibrosis** and macrophage infiltration were significantly attenuated in fasudil-treated animals. The migration of monocytes in vitro elicited by **N-formyl-methionyl-leucyl**-phenylalanine was potently inhibited by fasudil and its active metabolite, hydroxyfasudil. These results suggest that inhibition of Rho-kinase produces a reduction of macrophage infiltration and represents a new therapeutic strategy for renal **fibrosis**, a major factor in the progression to end-stage renal failure.

L17 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Altered intracellular pH regulation in neutrophils from patients with **cystic fibrosis**

AB **Cystic fibrosis** (CF) is a condition characterized by neutrophil-mediated lung damage and bacterial colonization. The physiologic basis for reported functional alterations in CF neutrophils, including increased release of neutrophil elastase, myeloperoxidase, and oxidants, is unknown. These processes are, however, regulated by intracellular pH (pHi). We demonstrate here that pHi regulation is altered in neutrophils from CF patients. Although resting pHi is similar, pHi after acid loading and activation (**N-formyl-methionyl-leucyl**-phenylalanine and phorbol 12-myristate 13-acetate) is more acidic in CF cells than in normal cells. Furthermore, patients with non-CF-related bronchiectasis handle acid loading and activation in a fashion similar to subjects with normal neutrophils, suggesting that chronic pulmonary inflammation alone does not explain the difference in pHi. This is further supported by data showing that normal neutrophils exposed to the CF pulmonary milieu respond by increasing pHi as opposed to decreasing pHi as seen in activated CF neutrophils. These pHi differences in activated or acid-loaded CF neutrophils are abrogated by ZnCl<sub>2</sub> but not by amiloride and bafilomycin A1, suggesting that passive proton conductance is abnormal in CF. In addition, DIDS, which inhibits HCO<sub>3</sub><sup>-</sup>/Cl<sup>-</sup> exchange, causes alkalinization of control but not of CF neutrophils, suggesting that anion transport is also abnormal in CF neutrophils. In summary, we have shown that pHi regulation in CF neutrophils is intrinsically abnormal, potentially contributing to the pulmonary manifestations of the condition.

L17 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis

AB Human neutrophils contain three isoforms of antimicrobial and cytotoxic peptides in the azurophilic granules, which belong to a family of mammalian neutrophil peptides named defensins. Here we investigate the role of these peptides in diffuse panbronchiolitis (DPB). Defensins (human neutrophil peptide-1, -2 and -3) were measured by RIA in bronchoalveolar lavage fluid (BALF) of 30 patients with DPB, 16 patients with idiopathic pulmonary **fibrosis** (IPF) and 15 healthy adults. The concentration of defensins was higher in BALF of patients with DPB than in patients with IPF and healthy subjects. DPB and IPF patients also had significantly higher plasma concns. of defensins than controls. In patients with DPB, BALF concentration of defensins correlated significantly with neutrophil count

or

BALF concentration of interleukin (IL)-8. Immunohistochem. of open-lung biopsy specimens from four DPB patients showed localization of defensins in neutrophils and mucinous exudate in the airways, and on the surface of bronchiolar epithelial cells. In vitro studies showed an enhanced extracellular release of defensins following stimulation of neutrophils with phorbol myristate acetate, **N-formyl-methionyl-leucyl**-phenylalanine, and human recombinant IL-8. Treatment of DPB with macrolides for 6 mo significantly reduced

neutrophil count and concns. of defensins and IL-8 in BALF. Our results indicate accumulation of neutrophil-derived defensins in the airway in diffuse panbronchiolitis, and suggest that defensins may be a marker of neutrophil activity in this disease.

L17 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Suppressive effect of tranilast, an anti-allergic drug, on pulmonary **fibrosis**

AB Treatment with tranilast in vitro suppressed the release of active O species from mice peritoneal macrophages and guinea pig alveolar macrophages stimulated with agents including phorbol myristate acetate, opsonized zymosan, and N-formyl-methionyl-leucyl-phenylalanine (FMLP). Tranilast given orally suppressed the development of pulmonary **fibrosis** in mice that had been injected with BLM intratracheally, and suppressed the activity of their alveolar macrophages to produce active O species, indicating that tranilast suppressed the activation of alveolar macrophages not only in vitro but also in vivo. These results suggest that tranilast suppressed the pulmonary **fibrosis** through inhibiting activation of alveolar macrophages.

L17 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Up-regulation of alveolar macrophage function and pulmonary **fibrosis**

AB The relationship between up-regulation of alveolar macrophage (AM) function and pulmonary **fibrosis** was studied using bleomycin (BLM)-induced pulmonary **fibrosis** model in guinea pigs. Pulmonary **fibrosis** was observed on day 30 of BLM injection and it developed continuously in the BLM group on day 50. Neutrophils appeared in the alveolar space on day 3 and reached maximum on day 10 in the BLM group. Between 1 and 10 days after BLM injection, O<sub>2</sub>- generation in AM was increased by TNF- $\alpha$ , but not spontaneously or by PMA or by N-formyl-methionyl-leucyl-phenylalanine (FMLP). Between 20 and 50 days after BLM injection, the BLM group and the control group did not differ in O<sub>2</sub>- generation in AM with stimulants of PMA, FMLP, TNF- $\alpha$ , or spontaneously. In guinea pigs with BLM-induced pulmonary **fibrosis**, the up-regulation of AM function could not be obtained as seen in idiopathic interstitial pneumonia (IIP) patients. Thus, the up-regulation in IIP patients may reflect the specific physiol. condition of IIP.

L17 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Alteration of the N-formyl-methionyl-leucyl-phenylalanine-induced response in cystic **fibrosis** neutrophils

AB To determine whether cystic **fibrosis** neutrophils are affected in their secretory functions, lysosomal enzyme release and chemiluminescence (light emission from cells) were assayed in patients' cells and compared with those in normal control cells. A decreased response was observed in cystic **fibrosis** neutrophils in  $\beta$ -glucuronidase release and chemiluminescence after stimulation by N-formylmethionylleucylphenylalanine (I). There was no correlation of these results with the clin. score nor with the medical treatment. Responses to the Ca ionophore A23187 and to opsonized zymosan showed no significant difference between normal and cystic **fibrosis** subjects in lysosomal enzyme release. I receptor alterations did not seem involved in the observed effect. Thus, there is a difference between normal and cystic **fibrosis** neutrophils in lysosomal enzyme release and chemiluminescence responses to I stimulation, a difference that might be located in the plasma membrane as both responses are membrane dependent.

=> d his

(FILE 'HOME' ENTERED AT 16:15:06 ON 04 FEB 2004)

FILE 'STNGUIDE' ENTERED AT 16:15:13 ON 04 FEB 2004

FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, FSTA, JAPIO, BIOSIS, CEN, CEABA-VTB, BIOBUSINESS, HCAPLUS' ENTERED AT 16:16:22 ON 04 FEB 2004

L1 993 S FIBROSIS () TREATMENT  
L2 45818 S FIBROSIS AND CIRRHOSIS  
L3 1 S CHRONIC PANCREATITUS  
L4 95 S L2 AND L1  
L5 2524 S F-MET-LEU  
L6 346 S N-FORMYL PEPTIDES  
L7 0 S L6 AND L1  
L8 1 S L5 AND L1  
L9 19 S L5 AND L6  
L10 365786 S FIBROSIS  
L11 0 S L10 AND VAS DEFERENS REPAIR  
L12 1 S L10 AND FALLOPIAN TUBE REPAIR  
L13 109111 S L10 AND THERAPY  
L14 1 S L13 AND L6  
L15 8 S ANTIFIBROTIC PEPTIDE  
L16 5176 S N-FORMYL-METHIONYL-LEUCYL  
L17 56 S L16 AND L10

=> d l17 ti abs ibib 40-56

L17 ANSWER 40 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Protection against acute lung injury by intravenous or intratracheal  
pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor.  
AB Excessive accumulation of active neutrophil elastase (NE) in pulmonary  
fluids and tissues of patients with cystic **fibrosis** (CF) is  
thought to act on the lungs, compromising their structure and function.  
The aim of this study was to investigate the in vitro and in vivo  
protective effect of a new, rapidly acting, potent ( $K_i = 5.45 \times 10^{-12}$  M  
and  $K_{on} = 8 \times 10^6$  M<sup>-1</sup> s<sup>-1</sup>) and specific human NE inhibitor, EPI-HNE-4,  
engineered from the Kunitz domain. The results demonstrated that this  
inhibitor was able to (i) effectively inhibit in vitro the high levels of  
active NE present in a medium as complex as sputum from children with CF,  
with a measured IC<sub>50</sub> equal or close to the calculated IC<sub>50</sub> in 60% of  
cases, and (ii) almost completely block (91%) the N-formyl-methionine-  
leucine-phenylalanine-induced migration of purified human neutrophils  
across a Matrigel basement membrane. Intratracheal administration (250,  
175, or 100 µg per rat) of the inhibitor 5 min before instillation of  
pure human NE (HNE) (150 µg per rat) to rats induced effective,  
dose-dependent protection of the lungs, 4 h later, from hemorrhage, serum  
albumin leakage, residual active NE, and discrete neutrophil influx in air  
spaces induced by instillation of pure HNE. Intravenous administration (3  
mg per rat) of EPI-HNE-4, 15 min before instillation of the soluble  
fraction of pooled sputum (delivering 120 µg of active NE per rat) from  
children with CF, effectively reduced (64%), 4 h later, the massive  
neutrophil influx induced by sputum instillation. Overall, these data  
strongly suggest that associated aerosol and systemic administration of  
EPI-HNE-4 would be beneficial in the treatment of CF.

ACCESSION NUMBER: 2002:229304 BIOSIS

DOCUMENT NUMBER: PREV200200229304

TITLE: Protection against acute lung injury by intravenous or  
intratracheal pretreatment with EPI-HNE-4, a new potent  
neutrophil elastase inhibitor.

AUTHOR(S): Delacourt, Christophe; Herigault, Sabine; Delclaux,  
Christophe; Poncin, Alain; Levame, Micheline; Harf, Alain;  
Saudubray, Francois; Lafuma, Chantal [Reprint author]

CORPORATE SOURCE: INSERM U492 de Physiopathologie et Therapeutique  
Respiratoires, Faculte de Medecine, 8 rue du General  
Sarrail, 94010, Creteil, France

lafuma@im3.inserm.fr  
SOURCE: American Journal of Respiratory Cell and Molecular Biology,  
(March, 2002) Vol. 26, No. 3, pp. 290-297. print.  
CODEN: AJRBEL. ISSN: 1044-1549.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 3 Apr 2002  
Last Updated on STN: 3 Apr 2002

L17 ANSWER 41 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Lipid and fatty acid imbalance and neutrophil function in cystic  
fibrosis.

ACCESSION NUMBER: 2001:91852 BIOSIS  
DOCUMENT NUMBER: PREV200100091852  
TITLE: Lipid and fatty acid imbalance and neutrophil function in  
cystic fibrosis.  
AUTHOR(S): Nixon, L. S. [Reprint author]; Ionescu, A. A. [Reprint  
author]; Shale, D. J. [Reprint author]  
CORPORATE SOURCE: Section of Respiratory Medicine, Academic Centre,  
University of Wales College of Medicine, Llandough  
Hospital, Penarth, Cardiff, CF64 2XX, UK  
SOURCE: Thorax, (December, 2000) Vol. 55, No. Supplement 3, pp.  
A66. print.  
Meeting Info.: Winter Meeting of the British Thoracic  
Society. Westminster, London, UK. December 13-15, 2000.  
British Thoracic Society.  
CODEN: THORA7. ISSN: 0040-6376.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 21 Feb 2001  
Last Updated on STN: 12 Feb 2002

L17 ANSWER 42 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Erythema elevatum diutinum: Evidence for disease-dependent leucocyte  
alterations and response to dapsone.  
AB Erythema elevatum diutinum (EED) is a type of leucocytoclastic vasculitis  
of unknown aetiology. We report a patient with unusually widespread and  
disabling EED that had been unresponsive to corticosteroids and  
antibiotics, but resolved on dapsone. Biopsies of fresh lesions showed  
typical features of leucocytoclastic vasculitis, with prominent neutrophil  
infiltration, marked expression of the beta2-integrins CR3 and LFA-1, and  
increased mast cell numbers. Older lesions exhibited granulation tissue  
and fibrosis, macrophages were more dominant, beta2-integrins  
were expressed less markedly, and mast cell numbers were lower. In vitro  
chemotaxis of the patient's peripheral blood neutrophils prior to  
treatment showed increased random migration and directed migration towards  
interleukin-8 (by 424%), but a profoundly decreased responsiveness towards  
the bacterial peptide analogue N-formyl-  
methionyl-leucyl-phenylalanine (fMLP) (by 98%). These  
values returned to normal after dapsone treatment and clinical improvement  
5 months later. These findings support the concept that in EED,  
activation via cytokines such as interleukin-8 allows a selective  
recruitment of leucocytes to tissue sites, while immune complexes and  
bacterial peptides sustain the persistent local inflammatory infiltrate  
and the leucocytoclastic vasculitis.

ACCESSION NUMBER: 2000:411111 BIOSIS  
DOCUMENT NUMBER: PREV200000411111  
TITLE: Erythema elevatum diutinum: Evidence for disease-dependent  
leucocyte alterations and response to dapsone.  
AUTHOR(S): Grabbe, J.; Haas, N.; Moeller, A.; Henz, B. M. [Reprint  
author]  
CORPORATE SOURCE: Department of Dermatology and Allergy, Charite, Humboldt  
University, Augustenburger-Platz 1, Campus Virchow Clinic,

SOURCE: D-13344, Berlin, Germany  
British Journal of Dermatology, (August, 2000) Vol. 143,  
No. 2, pp. 415-420. print.  
CODEN: BJDEAZ. ISSN: 0007-0963.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 27 Sep 2000  
Last Updated on STN: 8 Jan 2002

L17 ANSWER 43 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Altered intracellular pH regulation in neutrophils from patients with  
cystic **fibrosis**.

AB Cystic **fibrosis** (CF) is a condition characterized by  
neutrophil-mediated lung damage and bacterial colonization. The  
physiological basis for reported functional alterations in CF neutrophils,  
including increased release of neutrophil elastase, myeloperoxidase, and  
oxidants, is unknown. These processes are, however, regulated by  
intracellular pH (pHi). We demonstrate here that pHi regulation is  
altered in neutrophils from CF patients. Although resting pHi is similar,  
pHi after acid loading and activation (N-formyl-  
**methionyl-leucyl-phenylalanine** and phorbol 12-myristate  
13-acetate) is more acidic in CF cells than in normal cells. Furthermore,  
patients with non-CF-related bronchiectasis handle acid loading and  
activation in a fashion similar to subjects with normal neutrophils,  
suggesting that chronic pulmonary inflammation alone does not explain the  
difference in pHi. This is further supported by data showing that normal  
neutrophils exposed to the CF pulmonary milieu respond by increasing pHi  
as opposed to decreasing pHi as seen in activated CF neutrophils. These  
pHi differences in activated or acid-loaded CF neutrophils are abrogated  
by ZnCl<sub>2</sub> but not by amiloride and bafilomycin A1, suggesting that passive  
proton conductance is abnormal in CF. In addition, DIDS, which inhibits  
HCO<sub>3</sub><sup>-</sup>/Cl<sup>-</sup> exchange, causes alkalinization of control but not of CF  
neutrophils, suggesting that anion transport is also abnormal in CF  
neutrophils. In summary, we have shown that pHi regulation in CF  
neutrophils is intrinsically abnormal, potentially contributing to the  
pulmonary manifestations of the condition.

ACCESSION NUMBER: 2000:380904 BIOSIS  
DOCUMENT NUMBER: PREV200000380904  
TITLE: Altered intracellular pH regulation in neutrophils from  
patients with cystic **fibrosis**.  
AUTHOR(S): Coakley, Raymond J.; Taggart, Clifford; Canny, Gerry;  
Greally, Peter; O'Neill, Shane J.; McElvaney, Noel G.  
[Reprint author]  
CORPORATE SOURCE: Dept. of Medicine, Beaumont Hospital, Dublin 9, Ireland  
SOURCE: American Journal of Physiology, (July, 2000) Vol. 279, No.  
1 Part 1, pp. L66-L74. print.  
CODEN: AJPHAP. ISSN: 0002-9513.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 6 Sep 2000  
Last Updated on STN: 8 Jan 2002

L17 ANSWER 44 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Cystic **fibrosis** transmembrane conductance regulator does not  
affect neutrophil migration across cystic **fibrosis** airway  
epithelial monolayers.

AB Recent studies have shown that airway inflammation dominated by  
neutrophils, ie, polymorphonuclear cells (PMN) was observed in infants and  
children with cystic **fibrosis** (CF) even in the absence of  
detectable infection. To assess whether there is a CF-related anomaly of  
PMN migration across airway epithelial cells, we developed an in vitro  
model of chemotactic migration across tight and polarized CF15 cells, a CF  
human nasal epithelial cell line, seeded on porous filters. To compare  
PMN migration across a pair of CF and control monolayers in the

physiological direction, inverted CF15 cells were infected with increasing concentrations of recombinant adenoviruses containing either the normal cystic fibrosis transmembrane conductance regulator (CFTR) cDNA, the DELTAF508 CFTR cDNA, or the beta-galactosidase gene. The number of PMN migrating in response to N-formyl-Met-Leu-Phe across inverted CF15 monolayers expressing beta-galactosidase was similar to that seen across CF15 monolayers rescued with CFTR, whatever the proportion of cells expressing the transgene. Moreover, PMN migration across monolayers expressing various amounts of mutated CFTR was not different from that observed across matched counterparts expressing normal CFTR. Finally, PMN migration in response to adherent or *Pseudomonas aeruginosa* was equivalent across CF and corrected monolayers. The possibility that mutated CFTR may exert indirect effects on PMN recruitment, via an abnormal production of the chemotactic cytokine interleukin-8, was also explored. Apical and basolateral production of interleukin-8 by polarized CF cells expressing mutated CFTR was not different from that observed with rescued cells, either in baseline or stimulated conditions. CF15 cells displayed a CF phenotype that could be corrected by CFTR-containing adenoviruses, because two known CF defects, Cl<sup>-</sup> secretion and increased *P. aeruginosa* adherence, were normalized after infection with those viruses. Thus, we conclude that the presence of a mutated CFTR does not per se lead to an exaggerated inflammatory response of CF surface epithelial cells in the absence or presence of a bacterial infection.

ACCESSION NUMBER: 2000:334520 BIOSIS  
DOCUMENT NUMBER: PREV200000334520  
TITLE: Cystic fibrosis transmembrane conductance regulator does not affect neutrophil migration across cystic fibrosis airway epithelial monolayers.  
AUTHOR(S): Pizurki, Lara [Reprint author]; Morris, Michael A.; Chanson, Marc; Solomon, Melete; Pavirani, Andrea; Bouchardy, Isabelle; Suter, Susanne  
CORPORATE SOURCE: Laboratory of Clinical Investigation III, Hopital Cantonal Universitaire, 1211, Genève, 14, Switzerland  
SOURCE: American Journal of Pathology, (April, 2000) Vol. 156, No. 4, pp. 1407-1416. print.  
CODEN: AJPA44. ISSN: 0002-9440.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 10 Aug 2000  
Last Updated on STN: 7 Jan 2002

L17 ANSWER 45 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis.  
AB Human neutrophils contain three isoforms of antimicrobial and cytotoxic peptides in the azurophil granules, which belong to a family of mammalian neutrophil peptides named defensins. Here we investigate the role of these peptides in diffuse panbronchiolitis (DPB). Defensins (human neutrophil peptide-1, -2 and -3) were measured by radioimmunoassay in bronchoalveolar lavage fluid (BALF) of 30 patients with DPB, 16 patients with idiopathic pulmonary fibrosis (IPF) and 15 healthy adults. The concentration of defensins was higher in BALF of patients with DPB than in patients with IPF and healthy subjects. DPB and IPF patients also had significantly higher plasma concentrations of defensins than controls. In patients with DPB, BALF concentration of defensins correlated significantly with neutrophil count or BALF concentration of interleukin (IL)-8. Immunohistochemistry of open-lung biopsy specimens from four DPB patients showed localization of defensins in neutrophils and mucinous exudate in the airways, and on the surface of bronchiolar epithelial cells. In vitro studies showed an enhanced extracellular release of defensins following stimulation of neutrophils with phorbol myristate acetate, N-formyl-methionyl-leucyl -phenylamine, and human recombinant IL-8. Treatment of DPB with macrolides for 6 months significantly reduced neutrophil count and

concentrations of defensins and IL-8 in BALF. Our results indicate accumulation of neutrophil-derived defensins in the airway in diffuse panbronchiolitis, and suggest that defensins may be a marker of neutrophil activity in this disease.

ACCESSION NUMBER: 1998:166805 BIOSIS  
DOCUMENT NUMBER: PREV199800166805  
TITLE: Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis.  
AUTHOR(S): Ashitani, J.; Mukae, H. [Reprint author]; Nakazato, M.; Ihi, T.; Mashimoto, H.; Kadota, J.; Kohno, S.; Matsukura, S.  
CORPORATE SOURCE: Third Dep. Internal Med., Miyazaki Med. Coll., Kiyotake, Miyazaki 889-16, Japan  
SOURCE: European Respiratory Journal, (Jan., 1998) Vol. 11, No. 1, pp. 104-111. print.  
CODEN: ERJOEI. ISSN: 0903-1936.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 6 Apr 1998  
Last Updated on STN: 6 Apr 1998

L17 ANSWER 46 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI G proteins as biological targets for anti-allergic drugs?.  
AB The inhibiting effect of the H-1 antihistamine cetirizine on the release of mediators (LTB-4, arachidonic acid and phospholipase A2) was measured in different cells in vitro (human PMN, DELTA-F508 cells, chinese hamster ovary cells and rabbit chondrocytes) using different agonists (fMLP, NaF, calcium ionophore A 23187, bradykinin, adrenaline and IL-1). It was shown that physiological concentrations of the drug inhibited the release when activation of receptor-coupled G proteins was involved. By contrast, there was no inhibiting effect of cetirizine when the release was induced by a calcium ionophore which bypasses the G proteins coupled to cell membrane receptors.

ACCESSION NUMBER: 1997:255393 BIOSIS  
DOCUMENT NUMBER: PREV199799554596  
TITLE: G proteins as biological targets for anti-allergic drugs?.  
AUTHOR(S): Rihoux, J.-P. [Reprint author]; Masliah, J.; Bereziat, G.; Konig, W.  
CORPORATE SOURCE: UCB SA - Pharm. Sector, Chemin du Foriest, B-1420 Braine-l'Alleud, Belgium  
SOURCE: International Archives of Allergy and Immunology, (1997) Vol. 113, No. 1-3, pp. 339-341.  
CODEN: IAAIEG. ISSN: 1018-2438.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 13 Jun 1997  
Last Updated on STN: 13 Jun 1997

L17 ANSWER 47 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI DECREASED POLYMORPHONUCLEAR LEUCOCYTE CHEMOTACTIC RESPONSE TO LEUKOTRIENE B-4 IN CYSTIC FIBROSIS.  
AB Evidence that leukotriene B4 (LTB4) is a significant inflammatory mediator in chronic pseudomonal respiratory disease was sought in adolescents and young adults with cystic fibrosis. Specific chemotaxis of peripheral blood polymorphonuclear leucocytes (PMN) was used as an indirect measure of remote in vivo exposure to LTB4. PMN from 17 patients showed a significant decrease in chemotaxis to 10<sup>-7</sup>-10<sup>-9</sup> M LTB4, but normal responses to 10<sup>-8</sup> M n-formyl-methionyl-leucyl-phenylalanine and 4 mg/ml casein, when compared with 17 healthy age- and sex-matched controls. This results is consistent with chronic production of LTB4, and specific deactivation of circulating PMN receptors for LTB4 in patients with cystic fibrosis. Pharmacologic inhibition of LTB4 production in vivo may help elucidate its role in the pathogenesis of lung damage in cystic fibrosis.



ACCESSION NUMBER: 1992:455234 BIOSIS  
DOCUMENT NUMBER: PREV199294096634; BA94:96634  
TITLE: DECREASED POLYMORPHONUCLEAR LEUCOCYTE CHEMOTACTIC RESPONSE  
TO LEUKOTRIENE B-4 IN CYSTIC FIBROSIS.  
AUTHOR(S): LAWRENCE R H [Reprint author]; SORRELL T C  
CORPORATE SOURCE: CENTRE INFECTIOUS DISEASES MICROBIOL, WESTMEAD HOSP,  
WESTMEAD, NSW 2145, AUSTRALIA  
SOURCE: Clinical and Experimental Immunology, (1992) Vol. 89, No.  
2, pp. 321-324.  
CODEN: CEXIAL. ISSN: 0009-9104.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 7 Oct 1992  
Last Updated on STN: 8 Oct 1992

L17 ANSWER 48 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI INCREASED PHAGOCYTIC CELL CHEMILUMINESCENCE IN PATIENTS WITH CYSTIC  
FIBROSIS.

AB The oxidative burst of polymorphonuclear cells and monocytes from patients  
with cystic **fibrosis** as measured by luminol-enhanced  
chemiluminescence was examined after in vitro activation of the cells.  
All patients were outpatients at the time of the assays; their median age  
was 25.5 years (range, 12 to 33 years) and normal controls were young  
healthy adults. Stimulation of polymorphonuclear cells with phorbol  
myristate acetate, the chemotactic peptide **N-formyl-**  
**methionyl-leucyl**-phenylalanine, and the calcium  
ionophore A23187 resulted in significantly greater chemiluminescence  
responses from the cells of patients than from the control cells. The  
monocyte response of patients to opsonized zymosan was also greater than  
that of controls. Thus, phagocytic cells from adolescents and young  
adults with cystic **fibrosis** have a greater chemiluminescence  
response to a variety of stimuli. This may result in tissue damage in the  
lungs of these patients and thus make them more susceptible to pulmonary  
infections.

ACCESSION NUMBER: 1989:454133 BIOSIS  
DOCUMENT NUMBER: PREV198988102405; BA88:102405  
TITLE: INCREASED PHAGOCYTIC CELL CHEMILUMINESCENCE IN PATIENTS  
WITH CYSTIC FIBROSIS.  
AUTHOR(S): ROBERTS R L [Reprint author]; STIEHM R  
CORPORATE SOURCE: DEP PEDIATR, 22-387 MDCC, UCLA MED CENT, LOS ANGELES, CALIF  
90024, USA  
SOURCE: American Journal of Diseases of Children, (1989) Vol. 143,  
No. 8, pp. 944-950.  
CODEN: AJDCAI. ISSN: 0002-922X.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 4 Oct 1989  
Last Updated on STN: 4 Oct 1989

L17 ANSWER 49 OF 56 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN  
TI ALTERATION OF THE N FORMYLMETHIONYLLEUCYLPHENYLALANINE-INDUCED RESPONSE IN  
CYSTIC FIBROSIS NEUTROPHILS.

AB In order to determine whether cystic **fibrosis** neutrophils are  
affected in their secretory functions, lysosomal enzyme release and  
chemiluminescence (light emission from cells) were assayed in patients'  
cells and compared with those in normal control cells. We observed a  
decreased response of cystic **fibrosis** neutrophils in  
 $\beta$ -glucuronidase release and chemiluminescence after stimulation by  
**N-formyl-methionyl-leucyl**  
-phenylalanine. There was no significant correlation of these results  
with the clinical score nor with the medical treatment. On the other  
hand, responses to the calcium ionophore A23187 and to opsonized zymosan

showed no significant difference between normal and cystic fibrosis subjects in lysosomal enzyme release. N-formyl-methionyl-leucyl-phenylalanine receptor alterations did not seem involved in the observed effect as demonstrated by Scatchard plot analysis of N-formyl-methionyl-leucyl-phenylalanine binding to these receptors. These results clearly demonstrate a difference between normal and cystic fibrosis neutrophils in release and chemiluminescence responses to N-formyl-methionyl-leucyl-phenylalanine stimulation, a difference that might be located in the plasma membrane as both responses are membrane dependent.

ACCESSION NUMBER: 1986:297121 BIOSIS  
DOCUMENT NUMBER: PREV198682031027; BA82:31027  
TITLE: ALTERATION OF THE N FORMYLMETHIONYLLEUCYLPHENYLALANINE-INDUCED RESPONSE IN CYSTIC FIBROSIS NEUTROPHILS.  
AUTHOR(S): KEMP T [Reprint author]; SCHRAM-DOUMONT A; VAN GEFFEL R; KRAM R; SZPIRER C  
CORPORATE SOURCE: UNIV LIBRE BRUXELLES, DEP BIOLOGIE MOLECULAIRE, RUE DES CHEVAUX, 67, B-1640 RHODE-ST-GENESE, BELG  
SOURCE: Pediatric Research, (1986) Vol. 20, No. 6, pp. 520-526.  
CODEN: PEREBL. ISSN: 0031-3998.  
DOCUMENT TYPE: Article  
FILE SEGMENT: BA  
LANGUAGE: ENGLISH  
ENTRY DATE: Entered STN: 25 Jul 1986  
Last Updated on STN: 25 Jul 1986

L17 ANSWER 50 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils

AB Reactive oxygen species (ROS) are a common denominator of airway inflammation associated with chronic obstructive pulmonary disease (COPD) and asthma, as well as with less frequent lung diseases such as idiopathic pulmonary fibrosis (IPF), acute respiratory distress syndrome (ARDS) and cystic fibrosis (CF). The most frequently administered drugs used to treat these diseases are bronchodilators, antioxidant/antiphlogistic agents and mucoactive drugs. The metabolism of the mucoactive drug erdosteine produces an active metabolite (Met I) with a reducing SH group. In addition to its mucolytic action, Met I also has useful antioxidant activity. The various activities of  $\beta_2$ -agonists include their ability to reduce the respiratory burst of neutrophils and the subsequent release of ROS.  $\beta_2$ -Agonists and mucoactive drugs may be administered to the same patients during the treatment of lung diseases. The aim of this study was to investigate the ability of Met I to potentiate the activity of salbutamol in inhibiting the in vitro respiratory burst of neutrophils by means of chemiluminescence. The combination of Met I 5 and 10  $\mu$ g/mL with salbutamol  $10^{-5}$ ,  $10^{-6}$  and  $10^{-7}$  M led to a significant reduction in respiratory bursts when the neutrophils were stimulated with the soluble stimulant N-formyl-methionyl-leucyl-phenylalanine (fMLP). The combinations of the two drugs that reduced the respiratory bursts when a particulate stimulus (*Candida albicans*) was used were those containing  $10^{-5}$  M of salbutamol. The reasons for this different behavior remain unclear and raise questions about the specific roles, sites and mechanisms of action of the different types of stimulation undergone by the respiratory airways.

ACCESSION NUMBER: 2003:45121 HCAPLUS  
DOCUMENT NUMBER: 139:207474  
TITLE: The SH-metabolite I of erdosteine, a mucolytic drug, enhances the inhibitory effect of salbutamol on the respiratory burst of neutrophils  
AUTHOR(S): Dal Sasso, M.; Bovio, C.; Culici, M.; Fonti, E.; Braga, P. C.  
CORPORATE SOURCE: Center of Respiratory Pharmacology, Department of

Pharmacology, School of Medicine, University of Milan,  
Milan, Italy  
SOURCE: Drugs under Experimental and Clinical Research (2002),  
28(4), 147-154  
CODEN: DECRDP; ISSN: 0378-6501  
PUBLISHER: Bioscience Ediprint Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 51 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Fasudil attenuates interstitial **fibrosis** in rat kidneys with  
unilateral ureteral obstruction

AB This study was designed to investigate possible effects of the Rho-kinase  
inhibitor, fasudil, on the progression of renal failure in rats with  
unilateral ureteral obstruction. The renal failure markers monitored were  
the extent of renal interstitial **fibrosis** and that of macrophage  
infiltration. In kidneys with unilateral ureteral obstruction,  
interstitial **fibrosis** was observed, using Sirius-Red staining, on  
day 16 after unilateral ureteral obstruction. Macrophage infiltration was  
observed by immunohistochem., using the antibody, ED1. Interstitial  
**fibrosis** and macrophage infiltration were significantly attenuated  
in fasudil-treated animals. The migration of monocytes in vitro elicited  
by **N-formyl-methionyl-leucyl**  
-phenylalanine was potently inhibited by fasudil and its active  
metabolite, hydroxyfasudil. These results suggest that inhibition of  
Rho-kinase produces a reduction of macrophage infiltration and represents a  
new therapeutic strategy for renal **fibrosis**, a major factor in  
the progression to end-stage renal failure.

ACCESSION NUMBER: 2002:875345 HCAPLUS

DOCUMENT NUMBER: 139:30448

TITLE: Fasudil attenuates interstitial **fibrosis** in  
rat kidneys with unilateral ureteral obstruction

AUTHOR(S): Satoh, Shin-ichi; Yamaguchi, Tamami; Hitomi, Asako;  
Sato, Norihiro; Shiraiwa, Kazumi; Ikegaki, Ichiro;  
Asano, Toshio; Shimokawa, Hiroaki

CORPORATE SOURCE: Asahi Kasei Corporation, Institute of Life Science  
Research, Tagata-Gun, Shizuoka, 410-2321, Japan

SOURCE: European Journal of Pharmacology (2002), 455(2-3),  
169-174

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 52 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Altered intracellular pH regulation in neutrophils from patients with  
cystic **fibrosis**

AB Cystic **fibrosis** (CF) is a condition characterized by  
neutrophil-mediated lung damage and bacterial colonization. The physiol.  
basis for reported functional alterations in CF neutrophils, including  
increased release of neutrophil elastase, myeloperoxidase, and oxidants,  
is unknown. These processes are, however, regulated by intracellular pH  
(pHi). We demonstrate here that pHi regulation is altered in neutrophils  
from CF patients. Although resting pHi is similar, pHi after acid loading  
and activation (**N-formyl-methionyl-**  
**leucyl**-phenylalanine and phorbol 12-myristate 13-acetate) is more  
acidic in CF cells than in normal cells. Furthermore, patients with  
non-CF-related bronchiectasis handle acid loading and activation in a  
fashion similar to subjects with normal neutrophils, suggesting that  
chronic pulmonary inflammation alone does not explain the difference in

pHi. This is further supported by data showing that normal neutrophils exposed to the CF pulmonary milieu respond by increasing pHi as opposed to decreasing pHi as seen in activated CF neutrophils. These pHi differences in activated or acid-loaded CF neutrophils are abrogated by ZnCl<sub>2</sub> but not by amiloride and bafilomycin A1, suggesting that passive proton conductance is abnormal in CF. In addition, DIDS, which inhibits HCO<sub>3</sub><sup>-</sup>/Cl<sup>-</sup> exchange, causes alkalization of control but not of CF neutrophils, suggesting that anion transport is also abnormal in CF neutrophils. In summary, we have shown that pHi regulation in CF neutrophils is intrinsically abnormal, potentially contributing to the pulmonary manifestations of the condition.

ACCESSION NUMBER: 2000:539063 HCAPLUS  
 DOCUMENT NUMBER: 133:236133  
 TITLE: Altered intracellular pH regulation in neutrophils from patients with cystic **fibrosis**  
 AUTHOR(S): Coakley, Raymond J.; Taggart, Clifford; Canny, Gerry; Greally, Peter; O'Neill, Shane J.; McElvaney, Noel G.  
 CORPORATE SOURCE: Pulmonary Research Division, Beaumont Hospital, Dublin, 9, Ire.  
 SOURCE: American Journal of Physiology (2000), 279(1, Pt. 1), L66-L74  
 CODEN: AJPHAP; ISSN: 0002-9513  
 PUBLISHER: American Physiological Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 53 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis

AB Human neutrophils contain three isoforms of antimicrobial and cytotoxic peptides in the azurophil granules, which belong to a family of mammalian neutrophil peptides named defensins. Here we investigate the role of these peptides in diffuse panbronchiolitis (DPB). Defensins (human neutrophil peptide-1, -2 and -3) were measured by RIA in bronchoalveolar lavage fluid (BALF) of 30 patients with DPB, 16 patients with idiopathic pulmonary **fibrosis** (IPF) and 15 healthy adults. The concentration of defensins was higher in BALF of patients with DPB than in patients with IPF and healthy subjects. DPB and IPF patients also had significantly higher plasma concns. of defensins than controls. In patients with DPB, BALF concentration of defensins correlated significantly with neutrophil count

or

BALF concentration of interleukin (IL)-8. Immunohistochem. of open-lung biopsy specimens from four DPB patients showed localization of defensins in neutrophils and mucinous exudate in the airways, and on the surface of bronchiolar epithelial cells. In vitro studies showed an enhanced extracellular release of defensins following stimulation of neutrophils with phorbol myristate acetate, **N-formyl-methionyl-leucyl-phenylalanine**, and human recombinant IL-8. Treatment of DPB with macrolides for 6 mo significantly reduced neutrophil count and concns. of defensins and IL-8 in BALF. Our results indicate accumulation of neutrophil-derived defensins in the airway in diffuse panbronchiolitis, and suggest that defensins may be a marker of neutrophil activity in this disease.

ACCESSION NUMBER: 1998:188664 HCAPLUS  
 DOCUMENT NUMBER: 128:269454  
 TITLE: Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis  
 AUTHOR(S): Ashitani, J.; Mukae, H.; Nakazato, M.; Ihi, T.; Mashimoto, H.; Kadota, J.; Kohno, S.; Matsukura, S.  
 CORPORATE SOURCE: The Third Dept of Internal Medicine, Miyazaki Medical College, Miyazaki, 889-16, Japan

SOURCE: European Respiratory Journal (1998), 11(1), 104-111  
CODEN: ERJOEI; ISSN: 0903-1936  
PUBLISHER: Munksgaard International Publishers Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 54 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Suppressive effect of tranilast, an anti-allergic drug, on pulmonary  
**fibrosis**

AB Treatment with tranilast in vitro suppressed the release of active O  
species from mice peritoneal macrophages and guinea pig alveolar  
macrophages stimulated with agents including phorbol myristate acetate,  
opsonized zymosan, and N-formyl-methionyl-  
leucyl-phenylalanine (FMLP). Tranilast given orally suppressed  
the development of pulmonary **fibrosis** in mice that had been  
injected with BLM intratracheally, and suppressed the activity of their  
alveolar macrophages to produce active O species, indicating that  
tranilast suppressed the activation of alveolar macrophages not only in  
vitro but also in vivo. These results suggest that tranilast suppressed  
the pulmonary **fibrosis** through inhibiting activation of alveolar  
macrophages.

ACCESSION NUMBER: 1993:204900 HCAPLUS  
DOCUMENT NUMBER: 118:204900  
TITLE: Suppressive effect of tranilast, an anti-allergic  
drug, on pulmonary **fibrosis**  
AUTHOR(S): Daikoku, Michio; Tanaka, Hiroyuki; Mori, Hiroshi;  
Kawada, Kenji  
CORPORATE SOURCE: Sch. Med., Gifu Univ., Gifu, 500, Japan  
SOURCE: Gifu Daigaku Igakubu Kyo (1992), 40(6), 816-30  
CODEN: GDIKAN; ISSN: 0072-4521  
DOCUMENT TYPE: Journal  
LANGUAGE: Japanese

L17 ANSWER 55 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Up-regulation of alveolar macrophage function and pulmonary  
**fibrosis**

AB The relationship between up-regulation of alveolar macrophage (AM)  
function and pulmonary **fibrosis** was studied using bleomycin  
(BLM)-induced pulmonary **fibrosis** model in guinea pigs.  
Pulmonary **fibrosis** was observed on day 30 of BLM injection and it  
developed continuously in the BLM group on day 50. Neutrophils appeared  
in the alveolar space on day 3 and reached maximum on day 10 in the BLM group.  
Between 1 and 10 days after BLM injection, O<sub>2</sub>- generation in AM was  
increased by TNF- $\alpha$ , but not spontaneously or by PMA or by N  
-formyl-methionyl-leucyl-phenylalanine  
(FMLP). Between 20 and 50 days after BLM injection, the BLM group and the  
control group did not differ in O<sub>2</sub>- generation in AM with stimulants of  
PMA, FMLP, TNF- $\alpha$ , or spontaneously. In guinea pigs with BLM-induced  
pulmonary **fibrosis**, the up-regulation of AM function could not  
be obtained as seen in idiopathic interstitial pneumonia (IIP) patients.  
Thus, the up-regulation in IIP patients may reflect the specific physiol.  
condition of IIP.

ACCESSION NUMBER: 1992:589337 HCAPLUS  
DOCUMENT NUMBER: 117:189337  
TITLE: Up-regulation of alveolar macrophage function and  
pulmonary **fibrosis**  
AUTHOR(S): Ishihara, Yoko; Nagai, Atsushi; Kurashina, Naoko;  
Kagawa, Jun  
CORPORATE SOURCE: Dep. Hyg. Public Health, Tokyo Women's Med. Coll.,  
Tokyo, 162, Japan  
SOURCE: Igaku no Ayumi (1992), 162(8), 491-2  
CODEN: IGAYAY; ISSN: 0039-2359

DOCUMENT TYPE: Journal  
LANGUAGE: Japanese

L17 ANSWER 56 OF 56 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Alteration of the N-formyl-methionyl-leucyl-phenylalanine-induced response in cystic fibrosis neutrophils

AB To determine whether cystic fibrosis neutrophils are affected in their secretory functions, lysosomal enzyme release and chemiluminescence (light emission from cells) were assayed in patients' cells and compared with those in normal control cells. A decreased response was observed in cystic fibrosis neutrophils in  $\beta$ -glucuronidase release and chemiluminescence after stimulation by N-formylmethionylleucylphenylalanine (I). There was no correlation of these results with the clin. score nor with the medical treatment. Responses to the Ca ionophore A23187 and to opsonized zymosan showed no significant difference between normal and cystic fibrosis subjects in lysosomal enzyme release. I receptor alterations did not seem involved in the observed effect. Thus, there is a difference between normal and cystic fibrosis neutrophils in lysosomal enzyme release and chemiluminescence responses to I stimulation, a difference that might be located in the plasma membrane as both responses are membrane dependent.

ACCESSION NUMBER: 1986:477044 HCAPLUS

DOCUMENT NUMBER: 105:77044

TITLE: Alteration of the N-formyl-methionyl-leucyl-phenylalanine-induced response in cystic fibrosis neutrophils

AUTHOR(S): Kemp, Thierry; Schram-Doumont, Angele; Van Geffel, Rene; Kram, Raphael; Szpirer, Claude

CORPORATE SOURCE: Dep. Biol. Mol., Univ. Libre de Bruxelles, Rhode-St.-Genese, B-1640, Belg.

SOURCE: Pediatric Research (1986), 20(6), 520-6  
CODEN: PEREBL; ISSN: 0031-3998

DOCUMENT TYPE: Journal

LANGUAGE: English

## Refine Search

---

### Search Results -

Terms	Documents
6391856.pn.	1

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L6






---

### Search History

---

DATE: Wednesday, February 04, 2004    [Printable Copy](#)    [Create Case](#)

**Set Name Query**

side by side

**Hit Count Set Name**

result set

DB=USPT; PLUR=YES; OP=OR

<u>L6</u>	6391856.pn.	1	<u>L6</u>
<u>L5</u>	N-formyl-methionyl-leucyl	3	<u>L5</u>
<u>L4</u>	formyl peptide and L3	35501	<u>L4</u>
<u>L3</u>	L2 and l1	17040	<u>L3</u>
<u>L2</u>	hepatic fibrosis	19006	<u>L2</u>
<u>L1</u>	anti-fibrosis treatment	587275	<u>L1</u>

END OF SEARCH HISTORY

## Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6462020 B1

L5: Entry 1 of 3

File: USPT

Oct 8, 2002

US-PAT-NO: 6462020

DOCUMENT-IDENTIFIER: US 6462020 B1

TITLE: Small peptides and methods for treatment of asthma and inflammation

DATE-ISSUED: October 8, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Houck; John C.	late of Seattle	WA		
MacDonald; Mary	Lynden	WA		

US-CL-CURRENT: 514/18; 530/330

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

☐ 2. Document ID: US 6391856 B1

L5: Entry 2 of 3

File: USPT

May 21, 2002

US-PAT-NO: 6391856

DOCUMENT-IDENTIFIER: US 6391856 B1

TITLE: Method for treatment of allergic reaction using formyl peptide

DATE-ISSUED: May 21, 2002

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Houck; John C.	late of Seattle	WA		
Clagett; James	Snohomish	WA		

US-CL-CURRENT: 514/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------



☐ 3. Document ID: US 5753446 A

L5: Entry 3 of 3

File: USPT

May 19, 1998

US-PAT-NO: 5753446

DOCUMENT-IDENTIFIER: US 5753446 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Mitogen ERK kinase kinase (MEKK) assay

DATE-ISSUED: May 19, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Gary L.	Boulder	CO		

US-CL-CURRENT: 435/7.1; 435/252.3, 435/320.1, 435/325, 435/69.1, 530/300, 530/350, 536/23.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Figures	References	Claims	KWIC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	---------	------------	--------	------	----------

Clear

Generate Collection

Print

Fwd Refs

Bkwd Refs

Generate OACS

Terms

Documents

N-formyl-methionyl-leucyl

3

Display Format: CIT

Change Format

[Previous Page](#)[Next Page](#)[Go to Doc#](#)

## Hit List

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS				

### Search Results - Record(s) 1 through 3 of 3 returned.

☐ 1. Document ID: US 6462020 B1

L5: Entry 1 of 3

File: USPT

Oct 8, 2002

US-PAT-NO: 6462020

DOCUMENT-IDENTIFIER: US 6462020 B1

TITLE: Small peptides and methods for treatment of asthma and inflammation

DATE-ISSUED: October 8, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Houck; John C.	late of Seattle	WA		
MacDonald; Mary	Lynden	WA		

US-CL-CURRENT: 514/18; 530/330

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	References	Claims	KVMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	------------	--------	------	----------

☐ 2. Document ID: US 6391856 B1

L5: Entry 2 of 3

File: USPT

May 21, 2002

US-PAT-NO: 6391856

DOCUMENT-IDENTIFIER: US 6391856 B1

TITLE: Method for treatment of allergic reaction using formyl peptide

DATE-ISSUED: May 21, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Houck; John C.	late of Seattle	WA		
Clagett; James	Snohomish	WA		

US-CL-CURRENT: 514/18

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	References	Claims	KVMC	Draw. De
------	-------	----------	-------	--------	----------------	------	-----------	-----------	------------	--------	------	----------

☐ 3. Document ID: US 5753446 A

L5: Entry 3 of 3

File: USPT

May 19, 1998

US-PAT-NO: 5753446

DOCUMENT-IDENTIFIER: US 5753446 A

**\*\* See image for Certificate of Correction \*\***

TITLE: Mitogen ERK kinase kinase (MEKK) assay

DATE-ISSUED: May 19, 1998

## INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Johnson; Gary L.	Boulder	CO		

US-CL-CURRENT: 435/7.1; 435/252.3, 435/320.1, 435/325, 435/69.1, 530/300, 530/350, 536/23.1, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Drawings	Claims	KWIC	Draw. Des
------	-------	----------	-------	--------	----------------	------	-----------	-----------	----------	--------	------	-----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
N-formyl-methionyl-leucyl	3

Display Format:  [Previous Page](#)   [Next Page](#)   [Go to Doc#](#)

inserted into its constant region. The invention also provides vector, host cell and methods for production of the modified anti-TNF Igs. The invention also relates to formulation of modified anti-TNF Igs for therapeutic uses. The invention also relates to uses of modified anti-TNF Igs for treatments of immune disease, cancer and infection.

ACCESSION NUMBER: 2003:991031 HCAPLUS  
DOCUMENT NUMBER: 140:40889  
TITLE: Modified anti-tumor necrosis factor immunoglobulins containing extra constant region Ig domain inserted into its constant region and their therapeutic uses  
INVENTOR(S): Scallon, Bernard J.; Cai, Ann; Naso, Michael  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 37 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003232046	A1	20031218	US 2003-454948	20030605
WO 2003105898	A1	20031224	WO 2003-US17742	20030605
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR			

PRIORITY APPLN. INFO.: US 2002-388896P P 20020614

L4 ANSWER 16 OF 95 HCAPLUS COPYRIGHT 2004 ACS on STN  
TI Treatment of fibroproliferative disorders using TGF- $\beta$  inhibitors  
AB The invention concerns methods of treating fibroproliferative disorders associated with TGF- $\beta$  signaling, by administering non-peptide small mol. inhibitors of TGF- $\beta$  specifically binding to the type I TGF- $\beta$  receptor (TGF $\beta$ -R1). Preferably, the inhibitors are quinazoline derivs. The invention also concerns methods for reversing the effect of TGF- $\beta$  mediated cell activation on the expression of a gene associated with **fibrosis**, comprising contacting a cell or tissue in which the expression of such gene is altered as a result of TGF- $\beta$  mediated cell activation, with a non-peptide small mol. inhibitor of TGF- $\beta$ , specifically binding a TGF $\beta$ -R1 receptor kinase present in the cell or tissue.

ACCESSION NUMBER: 2003:931342 HCAPLUS  
DOCUMENT NUMBER: 140:791  
TITLE: Treatment of fibroproliferative disorders using TGF- $\beta$  inhibitors  
INVENTOR(S): Chakravarty, Sarvajit; Dugar, Sundeep; Higgins, Linda S.; Kapoun, Ann M.; Liu, David Y.; Schreiner, George F.; Protter, Andrew A.; Tran, Thomas-Toan  
PATENT ASSIGNEE(S): Scios, Inc., USA  
SOURCE: PCT Int. Appl., 114 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

WO 2003097615      A1      20031127      .      WO 2003-US15514      20030516

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,  
FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SK,  
SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW, AM, AZ, BY

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,  
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-381720P P 20020517

US 2003-440428 A 20030516

OTHER SOURCE(S) : MARPAT 140:791

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 95 HCAPLUS COPYRIGHT 2004 ACS on STN

## TI Lectins as antifibrotic agents

AB The invention discloses the treatment of tissue **fibrosis** by administration of an effective amount of a lectin. **Fibrosis** herein refers to the accumulation of extracellular matrix constituents that occurs following trauma, inflammation, tissue repair, immunol. reactions, cellular hyperplasia, and neoplasia. Examples of tissue **fibrosis** include, but are not limited to, pulmonary **fibrosis**, **cirrhosis** of the liver, skin scars and keloids, adhesions, fibromatosis, atherosclerosis, and amyloidosis. The treatment is intended for a variety of mammals, including humans.

ACCESSION NUMBER: 2003:912837 HCAPLUS

DOCUMENT NUMBER: 139:375056

TITLE: Lectins as antifibrotic agents

INVENTOR(S) : Cantor, Jerome Owen; Shteyngart, Bronislava

PATENT ASSIGNEE(S) : USA

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2003216300	A1	20031120	US 2003-435549	20030512
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2002-381367P P 20020520

L4 ANSWER 18 OF 95 HCAPLUS COPYRIGHT 2004 ACS on STN

TI Antiproliferative protein CHP-10 from *Hypericum perforatum* and uses for cancer therapy

AB A protein named CHP-10 has been isolated from *Hypericum perforatum* callus culture. This protein comprises a unique 20 amino acid sequence, has an apparent mol. weight of approx. 39 kDa by SDS-PAGE, and inhibits proliferation of abnormally proliferating cells from cancer or non-cancerous proliferative disorders. Methods of using CHP-10, or fragments, derivs., homologs and analogs of CHP-10, to inhibit the proliferation of abnormally proliferating cells are also provided.

ACCESSION NUMBER: 2003:892997 HCAPLUS

DOCUMENT NUMBER: 139:374996

TITLE: Antiproliferative protein CHP-10 from *Hypericum perforatum* and uses for cancer therapy

INVENTOR(S) : Khalili, Kamel; Sarkissian, Nune Darbinian

PATENT ASSIGNEE(S) : Temple University-of the Commonwealth System of Higher Education, USA